

**Editor: NOEL GONZÁLEZ GOTERA**  
**Diseño: Lic. Roberto Chávez y Liuder Machado.**  
**Foto: Lic. Belkis Romeu e Instituto Finlay**

**Número 084**  
**Semana 180513 - 240513**  
**La Habana, Cuba.**



## ARTÍCULOS CIENTÍFICOS

**Publicaciones incluidas en *PubMED* durante el período comprendido entre el 18 y el 24 de mayo de 2013. Con "vaccin\*" en título: **135** artículos recuperados.**

### Vacunas meningococo (*Neisseria meningitidis*)

8. [A Multi-Country Evaluation of \*Neisseria Meningitidis\* Serogroup B Factor H Binding Proteins and Implications for Vaccine Coverage in Different Age Groups.](#)

Hoiseth SK, Murphy E, Andrew L, Vogel U, Frosch M, Hellenbrand W, Abad R, Vazquez JA, Borrow R, Findlow J, Taha MK, Deghmane AE, Caugant DA, Kriz P, Musilek M, Mayer LW, Wang X, Macneil JR, York L, Tan CY, Jansen KU, Anderson AS.

Pediatr Infect Dis J. 2013 May 20. [Epub ahead of print]

PMID: 23694830  
[PubMed - as supplied by publisher]

### Related citations

Select item 23694748

28. [Cost-effectiveness analysis of introduction of meningococcal conjugate vaccine in Colombia, 2011.](#)

Castañeda-Orjuela CA, Alvis N, Coronel W, De la Hoz-Restrepo F.

Value Health. 2013 May;16(3):A89-90. doi: 10.1016/j.jval.2013.03.416. Epub 2013 May 3. No abstract available.

PMID: 23694615  
[PubMed - in process]

### Related citations

Select item 23694614

**Vacunas neumococo (*Streptococcus pneumoniae*)**

**12. Comorbid risk and correlates of pneumococcal vaccination among latent classes of older adults in the cross-sectional national health and wellness survey in Brazil.**

**Goren A, Roberts CS, Victor T.**

**Value Health. 2013 May;16(3):A97. doi: 10.1016/j.jval.2013.03.455. Epub 2013 May 3. No abstract available.**

**PMID: 23694660  
[PubMed - in process]**

**Related citations**

**Select item 23694659**

**12. Comorbid risk and correlates of pneumococcal vaccination among latent classes of older adults in the cross-sectional national health and wellness survey in Brazil.**

**Goren A, Roberts CS, Victor T.**

**Value Health. 2013 May;16(3):A97. doi: 10.1016/j.jval.2013.03.455. Epub 2013 May 3. No abstract available.**

**PMID: 23694660  
[PubMed - in process]**

**Related citations**

**Select item 23694659**

**16. Awareness and beliefs about pneumococcal and influenza vaccination among older african americans: Results from a survey of community-dwelling participants at an urban senior center.**

**Prioli KM, Schafer J, Fields Harris L, McCoy M, Barber E, Marthol-Clark M, Pizzi LT.**

**Value Health. 2013 May;16(3):A95. doi: 10.1016/j.jval.2013.03.445. Epub 2013 May 3. No abstract available.**

**PMID: 23694653  
[PubMed - in process]**

**Related citations**

**Select item 23694642**

**18. Cost-effectiveness of pneumococcal vaccines for adults in the United States.**

**Yang HK, Chen J, O'Brien M, Grabenstein J, Dasbach E.**

**Value Health. 2013 May;16(3):A93. doi: 10.1016/j.jval.2013.03.435. Epub 2013 May 3. No abstract available.**

**PMID: 23694640  
[PubMed - in process]**

[Related citations](#)

Select item 23694639

19. [Cost-effectiveness analysis of the available pneumococcal conjugated vaccines for children in Colombia.](#)

Ordoñez Molina JE, Orozco Giraldo JJ.

Value Health. 2013 May;16(3):A93. doi: 10.1016/j.jval.2013.03.434. Epub 2013 May 3. No abstract available.

PMID: 23694639

[PubMed - in process]

[Related citations](#)

Select item 23694638

20. [The cost-effectiveness analysis of pneumococcal 7-valent conjugate vaccine in china: A markov model.](#)

Fu Y, Liu GG, Ma A, Zhu L.

Value Health. 2013 May;16(3):A93. doi: 10.1016/j.jval.2013.03.433. Epub 2013 May 3. No abstract available.

PMID: 23694638

[PubMed - in process]

[Related citations](#)

Select item 23694636

24. [Cost effectiveness analysis of vaccination with 13-valent \(pcv13\) and 23-valent \(ppsv23\) pneumococcal vaccines for adults in bogota, Colombia - public scenario.](#)

Ordoñez Molina JE, Gutierrez-Ardila MV, Vargas Zea N.

Value Health. 2013 May;16(3):A90. doi: 10.1016/j.jval.2013.03.418. Epub 2013 May 3. No abstract available.

PMID: 23694627

[PubMed - in process]

[Related citations](#)

Select item 23694625

26. [Cost-effectiveness analysis of pneumococcal conjugate vaccination in urban china.](#)

Liu G, Zhu L, Deng J, Fu Y, Chu Y, Jin X, Shi Q.

Value Health. 2013 May;16(3):A90. doi: 10.1016/j.jval.2013.03.419. Epub 2013 May 3. No abstract available.

PMID: 23694624

[PubMed - in process]

[Related citations](#)

Select item 23694623

27. [Cost effectiveness analysis of vaccination with 13-valent \(pcv13\) and 23-valent \(ppsv23\) pneumococcal vaccines for adults in a private colombian institution.](#)

Ordoñez Molina JE, Gutierrez-Ardila MV, Vargas Zea N.

Value Health. 2013 May;16(3):A90. doi: 10.1016/j.jval.2013.03.417. Epub 2013 May 3. No abstract available.

PMID:

23694623  
[PubMed - in process]

[Related citations](#)

Select item 23694615

31. [Economic assessment of high-risk versus universal pediatric pcv13 vaccination programs in costa rica.](#)

Roberts CS, McGarry L, Gilmore K, Lutz MA, Strutton DR.

Value Health. 2013 May;16(3):A88. doi: 10.1016/j.jval.2013.03.408. Epub 2013 May 3. No abstract available.

PMID: 23694611

[PubMed - in process]

[Related citations](#)

Select item 23694599

33. [Budget impact evaluation of a vaccination with campaign program for corporations using pneumococcal conjugated vaccine \(pcv\) 13 valent versus pneumococcal polysaccharide vaccine \(ppv\) 23 with paid campaign for older adults.](#)

Fujii RK, Presa J, Roberts CS, Gea Y, Manfrin DF, Mould J.

Value Health. 2013 May;16(3):A84. doi: 10.1016/j.jval.2013.03.390. Epub 2013 May 3. No abstract available.

PMID: 23694592

[PubMed - in process]

[Related citations](#)

Select item 23694591

34. [Budget impact evaluation of a pneumococcal conjugated vaccine \(pcv\) 13 valent vaccination with free campaign program for corporations vesus no vaccination for older adults.](#)

Fujii RK, Presa J, Roberts CS, Gea Y, Manfrin DF, Mould J.

Value Health. 2013 May;16(3):A84. doi: 10.1016/j.jval.2013.03.389. Epub 2013 May 3. No abstract available.

**PMID:** 23694591  
[PubMed - in process]

[Related citations](#)

Select item 23694574

38. [Cost-effectiveness of 13-valent versus 23-valent pneumococcal polysaccharide vaccine and no vaccination in the czech national vaccination program.](#)

Zigmund J, Tichopad A, Kolek V, Roberts CS, Hajek P.

Value Health. 2013 May;16(3):A73-4. doi: 10.1016/j.jval.2013.03.331. Epub 2013 May 3. No abstract available.

**PMID:** 23694530  
[PubMed - in process]

[Related citations](#)

Select item 23694522

41. [Estimated public health impact of nationwide vaccination of infants with 7-valent pneumococcal conjugate vaccine \(pcv7\) in China.](#)

Hu S, Roberts CS, Du L, He JJ, Shi Q.

Value Health. 2013 May;16(3):A28. doi: 10.1016/j.jval.2013.03.163. Epub 2013 May 3. No abstract available.

**PMID:** 23694173  
[PubMed - in process]

[Related citations](#)

Select item 23693559

42. [Comparing vaccine effectiveness estimates in cost-effectiveness analyses of pneumococcal vaccination in adults.](#)

Yang HK, Mauskopf JA, Dasbach E.

Value Health. 2013 May;16(3):A17. doi: 10.1016/j.jval.2013.03.102. Epub 2013 May 3. No abstract available.

**PMID:** 23693559  
[PubMed - in process]

[Related citations](#)

Select item 23693469

75. [Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.](#)

Jackson LA, Gurtman A, Rice K, Pauksens K, Greenberg RN, Jones TR, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B.

Vaccine. 2013 May 17. doi:pii: S0264-410X(13)00588-4. 10.1016/j.vaccine.2013.05.010. [Epub ahead of print]

PMID: 23688527  
[PubMed - as supplied by publisher]

[Related citations](#)

Select item 23688526

76. [Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults.](#)

Jackson LA, Gurtman A, van Cleeff M, Jansen KU, Jayawardene D, Devlin C, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B.

Vaccine. 2013 May 17. doi:pii: S0264-410X(13)00587-2. 10.1016/j.vaccine.2013.04.085. [Epub ahead of print]

PMID: 23688526  
[PubMed - as supplied by publisher]

[Related citations](#)

Select item 23688525

77. [Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older.](#)

Jackson LA, Gurtman A, van Cleeff M, Frenck RW, Treanor J, Jansen KU, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B.

Vaccine. 2013 May 17. doi:pii: S0264-410X(13)00586-0. 10.1016/j.vaccine.2013.04.084. [Epub ahead of print]

PMID: 23688525  
[PubMed - as supplied by publisher]

[Related citations](#)

Select item 23688524

81. [Impact of 13-valent pneumococcal conjugate vaccine \(PCV13\) in a pandemic similar to the 2009 H1N1 in the United States.](#)

McGarry LJ, Gilmore KE, Rubin JL, Klugman KP, Strutton DR, Weinstein MC.

BMC Infect Dis. 2013 May 21;13(1):229. [Epub ahead of print]

PMID: 23687999  
[PubMed - as supplied by publisher]

[Free Article](#)

[Related citations](#)

Select item 23687584

**100. [Novel vaccine formulations against pertussis offer earlier onset of immunity and provide protection in the presence of maternal antibodies.](#)**

Polewicz M, Gracia A, Garlapati S, van Kessel J, Strom S, Halperin SA, Hancock RE, Potter AA, Babiuk LA, Gerdts V.

Vaccine. 2013 May 15. doi:pii: S0264-410X(13)00564-1. 10.1016/j.vaccine.2013.05.008. [Epub ahead of print]

PMID: 23684829  
[PubMed - as supplied by publisher]

[Related citations](#)

Select item 23684828

**103. [Epidemiology of invasive pneumococcal disease in the pre-conjugate vaccine era: South Africa, 2003–2008.](#)**

von Gottberg A, Cohen C, de Gouveia L, Meiring S, Quan V, Whitelaw A, Crowther-Gibson P, Madhi SA, Whitney CG, Klugman KP.

Vaccine. 2013 May 15. doi:pii: S0264-410X(13)00550-1. 10.1016/j.vaccine.2013.04.077. [Epub ahead of print]

PMID:  
23684826  
[PubMed - as supplied by publisher]

[Related citations](#)

Select item 23684825

**105. [Impact of pneumococcal conjugate vaccines on nasopharyngeal invasive disease among unvaccinated people: Review of evidence on indirect effects.](#)**

Davis S, Deloria-Knoll M, Kassa HT, O'Brien KL.

Vaccine. 2013 May 15. doi:pii: S0264-410X(13)00561-6. 10.1016/j.vaccine.2013.05.005. [Epub ahead of print]

PMID: 23684824  
[PubMed - as supplied by publisher]

[Related citations](#)

Select item 23684823

**106. [Immunogenicity and safety of pneumococcal conjugate polysaccharide and free polysaccharide vaccines alone or combined in HIV-infected adults in Brazil.](#)**

Ho YL, Brandão AP, de Cunto Brandileone MC, Lopes MH.

Vaccine. 2013 May 15. doi:pii: S0264-410X(13)00534-3. 10.1016/j.vaccine.2013.04.065. [Epub ahead of print]

PMID: 23684823  
[PubMed - as supplied by publisher]

[Related citations](#)

Select item 23684631

122. [Distribution of carried pneumococcal clones in UK children following the introduction of the 7-valent pneumococcal conjugate vaccine: A 3-year cross-sectional population based analysis.](#)

Tocheva AS, Jefferies JM, Christodoulides M, Faust SN, Clarke SC.

Vaccine. 2013 May 13. doi:pii: S0264-410X(13)00544-6. 10.1016/j.vaccine.2013.04.075. [Epub ahead of print]

PMID: 23680442  
[PubMed - as supplied by publisher]

[Related citations](#)

Select item 23680441

124. [Changes in Streptococcus pneumoniae serotype distribution in invasive disease and nasopharyngeal carriage after the heptavalent pneumococcal conjugate vaccine introduction in Bogotá, Colombia.](#)

Parra EL, Hoz FD, Díaz PL, Sanabria O, Realpe ME, Moreno JE.

Vaccine. 2013 May 13. doi:pii: S0264-410X(13)00543-4. 10.1016/j.vaccine.2013.04.074. [Epub ahead of print]

PMID:  
23680440  
[PubMed - as supplied by publisher]

[Related citations](#)

Select item 23680137

***Vacuna tosferina (Bordetella pertussis)***

6. [Association of Postpartum Maternal Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine \(Tdap\) Administration and Timeliness of Infant Immunization.](#)

Kaur I, George KJ, Pena-Ricardo C, Kelly BA, Watson B.

Pediatr Infect Dis J. 2013 May 20. [Epub ahead of print]

PMID: 23694833  
[PubMed - as supplied by publisher]

[Related citations](#)

Select item 23694831

9. [Acellular vaccines provided less protection during California pertussis outbreak.](#)

McCarthy M.

BMJ. 2013 May 21;346:f3325. doi: 10.1136/bmj.f3325. No abstract available.

PMID:

23694748

[PubMed - in process]

[Related citations](#)

Select item 23694667

60. [Comparative Effectiveness of Acellular Versus Whole-Cell Pertussis Vaccines in Teenagers.](#)

Klein NP, Bartlett J, Fireman B, Rowhani-Rahbar A, Baxter R.

Pediatrics. 2013 May 20. [Epub ahead of print]

PMID: 23690518

[PubMed - as supplied by publisher]

[Related citations](#)

Select item 23689897

Vacunas leptospirosis (Leptospira sp.)

79. [Pathogenic, diagnostic and vaccine potential of leptospiral outer membrane proteins \(OMPs\).](#)

Raja V, Natarajaseenivasan K.

Crit Rev Microbiol. 2013 May 21. [Epub ahead of print]

PMID: 23688248

[PubMed - as supplied by publisher]

[Related citations](#)

Select item 23688153

Vacunas, otras



1.

[When and for whom should booster hepatitis B vaccination be recommended?](#)

Wu TW, Lin HH, Wang LY.

Hepatology. 2013 May 20. doi: 10.1002/hep.26462. [Epub ahead of print] No abstract available.

PMID:

**23695983**  
[PubMed - as supplied by publisher]

[Related citations](#)

Select item 23695813  2.

[\*\*Chronic hepatitis B infection in adolescents vaccinated at birth: An alarm bell in favor of the need for a booster?\*\*](#)

Romanò L, Carsenti R, Tozzi AE, Mele A, Zanetti AR.

Hepatology. 2013 May 20. doi: 10.1002/hep.26458. [Epub ahead of print] No abstract available.

**PMID:**

**23695813**  
[PubMed - as supplied by publisher]

[Related citations](#)

Select item 23695441  3.

[\*\*Facile synthesis of tetrasaccharide aided by fluorous chemistry toward a dengue virus vaccine.\*\*](#)

Zhang Y, Liu B, Liu G.

Mol Divers. 2013 May 22. [Epub ahead of print]

**PMID:**

**23695441**  
[PubMed - as supplied by publisher]

[Related citations](#)

Select item 23695369  4.

[\*\*Vaccination, Herd Behavior, and Herd Immunity.\*\*](#)

Cohen MJ, Brezis M, Block C, Diederich A, Chinitz D.

Med Decis Making. 2013 May 21. [Epub ahead of print]

**PMID:**

**23695369**  
[PubMed - as supplied by publisher]

[Related citations](#)

Select item 23694839  5.

[Hepatitis B Virus Exposure during Childhood in Cameroon, Central African Republic and Senegal Following the Integration of HBV Vaccine in the Expanded Program on Immunization.](#)

Rey-Cuille MA, Njouom R, Bekondi C, Seck A, Gody C, Bata P, Garin B, Maylin S, Chartier L, Simon F, Vray M.

Pediatr Infect Dis J. 2013 May 20. [Epub ahead of print]

PMID:

23694839

[PubMed - as supplied by publisher]

[Related citations](#)

Select item 23694833  6.

[Association of Postpartum Maternal Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine \(Tdap\) Administration and Timeliness of Infant Immunization.](#)

Kaur I, George KJ, Pena-Ricardo C, Kelly BA, Watson B.

Pediatr Infect Dis J. 2013 May 20. [Epub ahead of print]

PMID:

23694833

[PubMed - as supplied by publisher]

[Related citations](#)

Select item 23694831  7.

[The Effectiveness of Varicella Vaccination in Children in Germany: A Case-Control Study.](#)

Liese JG, Cohen C, Rack A, Pirzer K, Eber S, Blum M, Greenberg M, Streng A.

Pediatr Infect Dis J. 2013 May 20. [Epub ahead of print]

PMID:

23694831

[PubMed - as supplied by publisher]

[Related citations](#)

Select item 23694830  8.

[\*\*A Multi-Country Evaluation of Neisseria Meningitidis Serogroup B Factor H Binding Proteins and Implications for Vaccine Coverage in Different Age Groups.\*\*](#)

Hoiseth SK, Murphy E, Andrew L, Vogel U, Frosch M, Hellenbrand W, Abad R, Vazquez JA, Borrow R, Findlow J, Taha MK, Deghmane AE, Caugant DA, Kriz P, Musilek M, Mayer LW, Wang X, Macneil JR, York L, Tan CY, Jansen KU, Anderson AS.

Pediatr Infect Dis J. 2013 May 20. [Epub ahead of print]

**PMID:**

[23694830](#)

[PubMed - as supplied by publisher]

[\*\*Related citations\*\*](#)

Select item 23694748  9.

[\*\*Acellular vaccines provided less protection during California pertussis outbreak.\*\*](#)

McCarthy M.

BMJ. 2013 May 21;346:f3325. doi: 10.1136/bmj.f3325. No abstract available.

**PMID:**

[23694748](#)

[PubMed - in process]

[\*\*Related citations\*\*](#)

Select item 23694667  10.

[\*\*Compliance with the birth dose of hepatitis B vaccine in high endemic and hard to reach areas in colombiaa.\*\*](#)

De la Hoz-Restrepo F, Choconta-Piraquive LA.

Value Health. 2013 May;16(3):A98. doi: 10.1016/j.jval.2013.03.459. Epub 2013 May 3. No abstract available.

**PMID:**

[23694667](#)

[PubMed - in process]

[\*\*Related citations\*\*](#)

Select item 23694664  11.

[\*\*Epidemiologic transition of hepatitis a in six countries and implications for vaccination policy: Data from a systematic literature review.\*\*](#)

Durden E, Maiese BA, Foley K.

**Value Health.** 2013 May;16(3):A98-9. doi: 10.1016/j.jval.2013.03.462. Epub 2013 May 3. No abstract available.

**PMID:**

23694664  
[PubMed - in process]

[Related citations](#)

Select item 23694660  12.

[Comorbid risk and correlates of pneumococcal vaccination among latent classes of older adults in the cross-sectional national health and wellness survey in Brazil.](#)

Goren A, Roberts CS, Victor T.

**Value Health.** 2013 May;16(3):A97. doi: 10.1016/j.jval.2013.03.455. Epub 2013 May 3. No abstract available.

**PMID:**

23694660  
[PubMed - in process]

[Related citations](#)

Select item 23694659  13.

[Disparities in influenza vaccinations among community pharmacy users and non-users.](#)

Munshi KD, Hong SH, Wang J.

**Value Health.** 2013 May;16(3):A97-8. doi: 10.1016/j.jval.2013.03.457. Epub 2013 May 3. No abstract available.

**PMID:**

23694659  
[PubMed - in process]

[Related citations](#)

Select item 23694657  14.

[Lessons from voluntary reporting of illinois hospital employee seasonal influenza vaccination rates \(2009-2013\).](#)

Paris B, Arahood T, Asche C, Amundson G.

**Value Health.** 2013 May;16(3):A96. doi: 10.1016/j.jval.2013.03.449. Epub 2013 May 3. No abstract available.

**PMID:**

**23694657**  
[PubMed - in process]

[Related citations](#)

Select item 23694654  15.

[Vaccination coverage in colombia, opportunity and factors associated: Results from a national survey.](#)

de La Hoz F, Osorio B, Narváez J.

**Value Health.** 2013 May;16(3):A96-7. doi: 10.1016/j.jval.2013.03.452. Epub 2013 May 3. No abstract available.

**PMID:**

**23694654**  
[PubMed - in process]

[Related citations](#)

Select item 23694653  16.

[Awareness and beliefs about pneumococcal and influenza vaccination among older african americans: Results from a survey of community-dwelling participants at an urban senior center.](#)

Prioli KM, Schafer J, Fields Harris L, McCoy M, Barber E, Marthol-Clark M, Pizzi LT.

**Value Health.** 2013 May;16(3):A95. doi: 10.1016/j.jval.2013.03.445. Epub 2013 May 3. No abstract available.

**PMID:**

**23694653**  
[PubMed - in process]

[Related citations](#)

Select item 23694642  17.

[Universal mass vaccination with quadrivalent influenza vaccine \(giv\) in the United States.](#)

Meier G, Clements KM, McGarry L, Pruttivarasin N, Misurski DA.

**Value Health.** 2013 May;16(3):A93-4. doi: 10.1016/j.jval.2013.03.437. Epub 2013 May 3. No abstract available.

**PMID:**

**23694642**  
[PubMed - in process]

[Related citations](#)

Select item 23694640  18.

[Cost-effectiveness of pneumococcal vaccines for adults in the United States.](#)

Yang HK, Chen J, O'Brien M, Grabenstein J, Dasbach E.

Value Health. 2013 May;16(3):A93. doi: 10.1016/j.jval.2013.03.435. Epub 2013 May 3.  
No abstract available.

**PMID:**

23694640  
[PubMed - in process]

[Related citations](#)

Select item 23694639  19.

[Cost-effectiveness analysis of the available pneumococcal conjugated vaccines for children in Colombia.](#)

Ordoñez Molina JE, Orozco Giraldo JJ.

Value Health. 2013 May;16(3):A93. doi: 10.1016/j.jval.2013.03.434. Epub 2013 May 3.  
No abstract available.

**PMID:**

23694639  
[PubMed - in process]

[Related citations](#)

Select item 23694638  20.

[The cost-effectiveness analysis of pneumococcal 7-valent conjugate vaccine in china: A markov model.](#)

Fu Y, Liu GG, Ma A, Zhu L.

Value Health. 2013 May;16(3):A93. doi: 10.1016/j.jval.2013.03.433. Epub 2013 May 3.  
No abstract available.

**PMID:**

23694638  
[PubMed - in process]

[Related citations](#)

Select item 23694636  21.

[The cost-effectiveness of hepatitis B vaccination using heplisav versus engerix-B in select adult populations in the United States.](#)

Kuan R, Janssen R, Heyward W, Nordyke R.

Value Health. 2013 May;16(3):A92. doi: 10.1016/j.jval.2013.03.427. Epub 2013 May 3. No abstract available.

PMID:

23694636  
[PubMed - in process]

[Related citations](#)

Select item 23694630  22.

[Potential epidemiological and economic impact of different rotavirus vaccines in low and middle income countries.](#)

Paternina-Caicedo A, De la Hoz-Restrepo F, Carrasquilla-Sotomayor M, Alvis-Zakzuk N, Alvis-Guzmán N.

Value Health. 2013 May;16(3):A91. doi: 10.1016/j.jval.2013.03.424. Epub 2013 May 3. No abstract available.

PMID:

23694630  
[PubMed - in process]

[Related citations](#)

Select item 23694628  23.

[Impact of vaccination coverage on cost-effectiveness of influenza vaccine at preventing hospitalization.](#)

You J.

Value Health. 2013 May;16(3):A91-2. doi: 10.1016/j.jval.2013.03.426. Epub 2013 May 3. No abstract available.

PMID:

23694628  
[PubMed - in process]

[Related citations](#)

Select item 23694627  24.

[Cost effectiveness analysis of vaccination with 13-valent \(pcv13\) and 23-valent \(ppsv23\) pneumococcal vaccines for adults in bogota, Colombia - public scenario.](#)

Ordoñez Molina JE, Gutierrez-Ardila MV, Vargas Zea N.

Value Health. 2013 May;16(3):A90. doi: 10.1016/j.jval.2013.03.418. Epub 2013 May 3.  
No abstract available.

PMID:

23694627  
[PubMed - in process]

[Related citations](#)

Select item 23694625  25.

[Cost-effectiveness comparison of quadrivalent versus trivalent influenza vaccines in the United States.](#)

Pitman RJ, Nagy LD, Antonova E, Scott DA.

Value Health. 2013 May;16(3):A90. doi: 10.1016/j.jval.2013.03.420. Epub 2013 May 3.  
No abstract available.

PMID:

23694625  
[PubMed - in process]

[Related citations](#)

Select item 23694624  26.

[Cost-effectiveness analysis of pneumococcal conjugate vaccination in urban china.](#)

Liu G, Zhu L, Deng J, Fu Y, Chu Y, Jin X, Shi Q.

Value Health. 2013 May;16(3):A90. doi: 10.1016/j.jval.2013.03.419. Epub 2013 May 3.  
No abstract available.

PMID:

23694624  
[PubMed - in process]

[Related citations](#)

Select item 23694623  27.

[Cost effectiveness analysis of vaccination with 13-valent \(pcv13\) and 23-valent \(ppsv23\) pneumococcal vaccines for adults in a private colombian institution.](#)

Ordoñez Molina JE, Gutierrez-Ardila MV, Vargas Zea N.

**Value Health. 2013 May;16(3):A90. doi: 10.1016/j.jval.2013.03.417. Epub 2013 May 3.  
No abstract available.**

**PMID:**

**23694623  
[PubMed - in process]**

[Related citations](#)

Select item 23694615  28.

[Cost-effectiveness analysis of introduction of meningococcal conjugate vaccine in Colombia, 2011.](#)

**Castañeda-Orjuela CA, Alvis N, Coronel W, De la Hoz-Restrepo F.**

**Value Health. 2013 May;16(3):A89-90. doi: 10.1016/j.jval.2013.03.416. Epub 2013 May 3. No abstract available.**

**PMID:**

**23694615  
[PubMed - in process]**

[Related citations](#)

Select item 23694614  29.

[Potential benefits analysis of quadrivalent influenza vaccine \(qiv\) on influenza disease burden in the United Kingdom, year by year analysis \(2000-2010\).](#)

**Meier G, Van Bellinghen LA, Van Vlaenderen I.**

**Value Health. 2013 May;16(3):A89. doi: 10.1016/j.jval.2013.03.415. Epub 2013 May 3.  
No abstract available.**

**PMID:**

**23694614  
[PubMed - in process]**

[Related citations](#)

Select item 23694612  30.

[Public health impact and cost effectiveness of hepatitis A vaccination in the United States: A population-based dynamic model.](#)

**Dhankhar P, Nwankwo C, Pillsbury M, Lauschke A, Goveia M, Acosta CJ, Elbasha EH.**

**Value Health. 2013 May;16(3):A88. doi: 10.1016/j.jval.2013.03.407. Epub 2013 May 3.  
No abstract available.**

**PMID:**

23694612  
[PubMed - in process]

[Related citations](#)

Select item 23694611  31.

[Economic assessment of high-risk versus universal pediatric pcv13 vaccination programs in costa rica.](#)

**Roberts CS, McGarry L, Gilmore K, Lutz MA, Strutton DR.**

**Value Health.** 2013 May;16(3):A88. doi: 10.1016/j.jval.2013.03.408. Epub 2013 May 3.  
No abstract available.

**PMID:**

23694611  
[PubMed - in process]

[Related citations](#)

Select item 23694599  32.

[Estimated human and economic burden of four major adult vaccine-preventable diseases in the United States, 2010.](#)

**McLaughlin JM.**

**Value Health.** 2013 May;16(3):A86. doi: 10.1016/j.jval.2013.03.400. Epub 2013 May 3.  
No abstract available.

**PMID:**

23694599  
[PubMed - in process]

[Related citations](#)

Select item 23694592  33.

[Budget impact evaluation of a vaccination with campaign program for corporations using pneumococcal conjugated vaccine \(pcv\) 13 valent versus pneumococcal polysaccharide vaccine \(ppv\) 23 with paid campaign for older adults.](#)

**Fujii RK, Presa J, Roberts CS, Gea Y, Manfrin DF, Mould J.**

**Value Health.** 2013 May;16(3):A84. doi: 10.1016/j.jval.2013.03.390. Epub 2013 May 3.  
No abstract available.

**PMID:**

23694592  
[PubMed - in process]

[Related citations](#)

Select item 23694591  34.

[Budget impact evaluation of a pneumococcal conjugated vaccine \(pcv\) 13 valent vaccination with free campaign program for corporations vesus no vaccination for older adults.](#)

Fujii RK, Presa J, Roberts CS, Gea Y, Manfrin DF, Mould J.

Value Health. 2013 May;16(3):A84. doi: 10.1016/j.jval.2013.03.389. Epub 2013 May 3.  
No abstract available.

PMID:

23694591  
[PubMed - in process]

[Related citations](#)

Select item 23694574  35.

[Effectiveness of the rotavirus monovalent vaccine in Colombia: preliminary results of a case-control study.](#)

Paternina-Caicedo A, Cotes K, Coronell-Rodriguez W, Alvis-Guzmán N, De la Hoz-Restrepo F.

Value Health. 2013 May;16(3):A81. doi: 10.1016/j.jval.2013.03.371. Epub 2013 May 3.  
No abstract available.

PMID:

23694574  
[PubMed - in process]

[Related citations](#)

Select item 23694569  36.

[Effectiveness of the monovalent rotavirus vaccine in Colombia through different analyses within an ecological study.](#)

Paternina-Caicedo A, Alvis-Guzmán N, Alvis-Zakzuk N, Carrasquilla-Sotomayor M, De la Hoz-Restrepo F.

Value Health. 2013 May;16(3):A80. doi: 10.1016/j.jval.2013.03.368. Epub 2013 May 3.  
No abstract available.

PMID:

23694569  
[PubMed - in process]

[Related citations](#)

Select item 23694553  37.

[\*\*Impact Of Doctors' Recommendations On Seasonal And H1N1 Flu Vaccinations For Medicaid/State Children's Health Insurance Program \(Schip\) Children During The 2009 H1N1 Flu Pandemic.\*\*](#)

Villacorta R.

**Value Health.** 2013 May;16(3):A78. doi: 10.1016/j.jval.2013.03.356. Epub 2013 May 3. No abstract available.

**PMID:**

23694553  
[PubMed - in process]

[\*\*Related citations\*\*](#)

Select item 23694530  38.

[\*\*Cost-effectiveness of 13-valent versus 23-valent pneumococcal polysaccharide vaccine and no vaccination in the czech national vaccination program.\*\*](#)

Zigmond J, Tichopad A, Kolek V, Roberts CS, Hajek P.

**Value Health.** 2013 May;16(3):A73-4. doi: 10.1016/j.jval.2013.03.331. Epub 2013 May 3. No abstract available.

**PMID:**

23694530  
[PubMed - in process]

[\*\*Related citations\*\*](#)

Select item 23694522  39.

[\*\*Health economics assessment of rotavirus vaccines in Mexico.\*\*](#)

Carlos F, Gomez JA, Anaya P, Standaert B, Carreño-Manjarrez R.

**Value Health.** 2013 May;16(3):A72. doi: 10.1016/j.jval.2013.03.324. Epub 2013 May 3. No abstract available.

**PMID:**

23694522  
[PubMed - in process]

[\*\*Related citations\*\*](#)

Select item 23694195  40.

[Economic evaluation of influenza vaccination in preventing hospitalization in cardiovascular disease patients.](#)

**Peasah SK, Meltzer M.**

**Value Health. 2013 May;16(3):A283. doi: 10.1016/j.jval.2013.03.1466. Epub 2013 May 3. No abstract available.**

**PMID:**

**23694195**  
[PubMed - in process]

[Related citations](#)

Select item 23694173  41.

[Estimated public health impact of nationwide vaccination of infants with 7-valent pneumococcal conjugate vaccine \(pcv7\) in China.](#)

**Hu S, Roberts CS, Du L, He JJ, Shi Q.**

**Value Health. 2013 May;16(3):A28. doi: 10.1016/j.jval.2013.03.163. Epub 2013 May 3. No abstract available.**

**PMID:**

**23694173**  
[PubMed - in process]

[Related citations](#)

Select item 23693559  42.

[Comparing vaccine effectiveness estimates in cost-effectiveness analyses of pneumococcal vaccination in adults.](#)

**Yang HK, Mauskopf JA, Dasbach E.**

**Value Health. 2013 May;16(3):A17. doi: 10.1016/j.jval.2013.03.102. Epub 2013 May 3. No abstract available.**

**PMID:**

**23693559**  
[PubMed - in process]

[Related citations](#)

Select item 23693469  43.

[Evaluation of direct-to-consumer advertising activities concerning human papilloma virus vaccines through mass media in thailand.](#)

Rattanamahattana M, Phosi P.

**Value Health.** 2013 May;16(3):A153-4. doi: 10.1016/j.jval.2013.03.760. Epub 2013 May 3. No abstract available.

**PMID:**

23693469  
[PubMed - in process]

[Related citations](#)

Select item 23693132  44.

[Hepatitis B vaccination status and associated factors among health care workers in Burkina Faso.](#)

Ouédraogo HG, Kouanda S, Tiendrébeogo S, Konseimbo GA, Yetta CE, Tiendrébeogo E, Savadogo AA, Sondo B.

**Med Sante Trop.** 2013 May 22. [Epub ahead of print]

**PMID:**

23693132  
[PubMed - as supplied by publisher]

[Related citations](#)

Select item 23692926  45.

[Dose-dependent immunogenicity of a soluble \*Neospora caninum\* tachyzoite-extract vaccine formulated with a soy lecithin/β-glucan adjuvant in cattle.](#)

Mansilla FC, Czepluch W, Malacari DA, Hecker YP, Bucafusco D, Franco-Mahecha OL, Moore DP, Capozzo AV.

**Vet Parasitol.** 2013 Apr 26. doi:pii: S0304-4017(13)00252-5.  
10.1016/j.vetpar.2013.04.040. [Epub ahead of print]

**PMID:**

23692926  
[PubMed - as supplied by publisher]

[Related citations](#)

Select item 23692824  46.

[In pursuit of an HIV vaccine: an interview with Andrew McMichael.](#)

McMichael AJ.

**BMC Biol.** 2013 May 21;11:60. doi: 10.1186/1741-7007-11-60. No abstract available.

**PMID:**

23692824  
[PubMed - in process]

[Related citations](#)

Select item 23692718  47.

[Long-term epidemiologic longitudinal study on the effect of vaccines on public inoculation.](#)

Matsuoka I, Matsuoka T, Matsuoka A, Shigemura T, Agematsu K, Koike K.

Turk J Pediatr. 2012 Jul-Aug;54(4):376-81.

**PMID:**

23692718  
[PubMed - in process]

[Related citations](#)

Select item 23692696  48.

[Reproductive performance of high producing lactating cows in Coxiella-infected herds following vaccination with phase-I Coxiella burnetii vaccine during advanced pregnancy.](#)

López-Helguera I, López-Gatius F, Tutusaus J, García-Inspero I.

Vaccine. 2013 May 10. doi:pii: S0264-410X(13)00536-7.  
10.1016/j.vaccine.2013.04.067. [Epub ahead of print]

**PMID:**

23692696  
[PubMed - as supplied by publisher]

[Related citations](#)

Select item 23692602  49.

[Immunogenicity of pandemic influenza A H1N1/2009 adjuvanted vaccine in pediatric solid organ transplant recipients.](#)

Gavaldà J, Cabral E, Pérez-Romero P, Len O, Aydillo T, Campins M, Quintero J, Peghin M, Nieto J, Charco R, Pahissa A, Cordero E; Spanish Network for the Research in Infectious Diseases (REIPI).

Pediatr Transplant. 2013 Jun;17(4):403-6. doi: 10.1111/petr.12084.

**PMID:**

23692602  
[PubMed - in process]

[Related citations](#)

Select item 23692596  50.

[Using HPV vaccination for promotion of an adolescent package of care: opportunity and perspectives.](#)

Macphail C, Venables E, Rees H, Delany-Moretlwe S.

BMC Public Health. 2013 May 21;13(1):493. [Epub ahead of print]

PMID:

23692596  
[PubMed - as supplied by publisher]

[Related citations](#)

Select item 23692077  51.

[Assessment of Heterogeneity of Efficacy of a Three-Dose Regimen of a Type III Secreted Protein Vaccine for Reducing STEC O157 in Feces of Feedlot Cattle.](#)

Vogstad AR, Moxley RA, Erickson GE, Klopfenstein TJ, Smith DR.

Foodborne Pathog Dis. 2013 May 21. [Epub ahead of print]

PMID:

23692077  
[PubMed - as supplied by publisher]

[Related citations](#)

Select item 23687737  52.

[Strengthened standards on flu vaccinations to pressure hospitals for progress.](#)

[No authors listed]

ED Manag. 2012 Mar;24(3):suppl 1-3.

PMID:

23687737  
[PubMed - in process]

[Related citations](#)

Select item 23691175  53.

[\*\*Risk Perception, Preventive Behaviors, and Vaccination Coverage in the Korean Population during the 2009-2010 Pandemic Influenza A \(H1N1\): Comparison between High-Risk Group and Non-High-Risk Group.\*\*](#)

Heo JY, Chang SH, Go MJ, Kim YM, Gu SH, Chun BC.

PLoS One. 2013 May 17;8(5):e64230. doi: 10.1371/journal.pone.0064230. Print 2013.

PMID:

23691175  
[PubMed - in process]

[Free Article](#)

[Related citations](#)

Select item 23691069  54.

[\*\*Broadening of the T-Cell Repertoire to HIV-1 Gag p24 by Vaccination of HLA-A2/DR Transgenic Mice with Overlapping Peptides in the CAF05 Adjuvant.\*\*](#)

Korsholm KS, Karlsson I, Tang ST, Brandt L, Agger EM, Aagaard C, Andersen P, Fomsgaard A.

PLoS One. 2013 May 17;8(5):e63575. doi: 10.1371/journal.pone.0063575. Print 2013.

PMID:

23691069  
[PubMed - in process]

[Free Article](#)

[Related citations](#)

Select item 23690999  55.

[\*\*Recombinant Vaccines against T. gondii: Comparison between Homologous and Heterologous Vaccination Protocols Using Two Viral Vectors Expressing SAG1.\*\*](#)

Mendes EA, Fonseca FG, Casério BM, Colina JP, Gazzinelli RT, Caetano BC.

PLoS One. 2013 May 15;8(5):e63201. doi: 10.1371/journal.pone.0063201. Print 2013.

PMID:

23690999  
[PubMed - in process]

[Free Article](#)

[Related citations](#)

Select item 23690682  56.

[Enhanced immune response against HIV-1 induced by a heterologous DNA prime-adenovirus boost vaccination using mannosylated polyethyleneimine as DNA vaccine adjuvant.](#)

Li M, Jiang Y, Xu C, Zhang Z, Sun X.

Int J Nanomedicine. 2013;8:1843-54. doi: 10.2147/IJN.S43827. Epub 2013 May 9.

PMID:

23690682  
[PubMed - in process]

[Free Article](#)

[Related citations](#)

Select item 23690681  57.

[Formulation, characterization, and expression of a recombinant MOMP Chlamydia trachomatis DNA vaccine encapsulated in chitosan nanoparticles.](#)

Cambridge CD, Singh SR, Waffo AB, Fairley SJ, Dennis VA.

Int J Nanomedicine. 2013;8:1759-71. doi: 10.2147/IJN.S42723. Epub 2013 May 10.

PMID:

23690681  
[PubMed - in process]

[Free Article](#)

[Related citations](#)

Select item 23690603  58.

[Deliberate reduction of hemagglutinin and neuraminidase expression of influenza virus leads to an ultraprotective live vaccine in mice.](#)

Yang C, Skiena S, Futcher B, Mueller S, Wimmer E.

Proc Natl Acad Sci U S A. 2013 May 20. [Epub ahead of print]

PMID:

23690603  
[PubMed - as supplied by publisher]

[Free Article](#)

[Related citations](#)

Select item 23690587  59.

[Deciphering the impacts of vaccination and immunity on pertussis epidemiology in Thailand.](#)

**Blackwood JC, Cummings DA, Broutin H, Iamsirithaworn S, Rohani P.**

**Proc Natl Acad Sci U S A. 2013 May 20. [Epub ahead of print]**

**PMID:**

**23690587**

**[PubMed - as supplied by publisher]**

[\*\*Free Article\*\*](#)

[\*\*Related citations\*\*](#)

Select item 23690518  60.

[\*\*Comparative Effectiveness of Acellular Versus Whole-Cell Pertussis Vaccines in Teenagers.\*\*](#)

**Klein NP, Bartlett J, Fireman B, Rowhani-Rahbar A, Baxter R.**

**Pediatrics. 2013 May 20. [Epub ahead of print]**

**PMID:**

**23690518**

**[PubMed - as supplied by publisher]**

[\*\*Related citations\*\*](#)

Select item 23689897  61.

[\*\*Opportunities in diagnostic and vaccine approaches to mitigate potential heartwater spreading and impact on the american mainland.\*\*](#)

**Vachiéry N, Marcelino I, Martinez D, Lefrançois T.**

**Dev Biol (Basel). 2013;135:191-200. doi: 10.1159/000190050. Epub 2013 May 14.**

**PMID:**

**23689897**

**[PubMed - in process]**

[\*\*Related citations\*\*](#)

Select item 23689892  62.

[\*\*Prospects for development of african Swine Fever virus vaccines.\*\*](#)

**Dixon LK, Abrams CC, Chapman DD, Goatley LC, Netherton CL, Taylor G, Takamatsu HH.**

**Dev Biol (Basel). 2013;135:147-57. doi: 10.1159/000170936. Epub 2013 May 14.**

**PMID:**

23689892  
[PubMed - in process]

[Related citations](#)

Select item 23689890  63.

[Passive Immunization and Active Vaccination against Hendra and Nipah Viruses.](#)

Broder CC.

*Dev Biol (Basel).* 2013;135:125-38. doi: 10.1159/000171017. Epub 2013 May 14.

**PMID:**

23689890  
[PubMed - in process]

[Related citations](#)

Select item 23689888  64.

[Novel Approaches to Foot-and-Mouth Disease Vaccine Development.](#)

Ludi A, Rodriguez L.

*Dev Biol (Basel).* 2013;135:107-16. doi: 10.1159/000313913. Epub 2013 May 14.

**PMID:**

23689888  
[PubMed - in process]

[Related citations](#)

Select item 23689887  65.

[Newcastle disease: progress and gaps in the development of vaccines and diagnostic tools.](#)

Afonso CL, Miller PJ.

*Dev Biol (Basel).* 2013;135:95-106. doi: 10.1159/000178459. Epub 2013 May 14.

**PMID:**

23689887  
[PubMed - in process]

[Related citations](#)

Select item 23689886  66.

[Current status and future needs in diagnostics and vaccines for high pathogenicity avian influenza.](#)

Swayne DE, Spackman E.

*Dev Biol (Basel).* 2013;135:79-94. doi: 10.1159/000325276. Epub 2013 May 14.

PMID:

23689886  
[PubMed - in process]

[Related citations](#)

Select item 23689884  67.

[State of the art, progress and gaps in development of vaccines and diagnostics for high priority transboundary diseases for the NVS.](#)

Dungu B, Donadeu M, Bouloy M.

*Dev Biol (Basel).* 2013;135:61-72. doi: 10.1159/000157178. Epub 2013 May 14.

PMID:

23689884  
[PubMed - in process]

[Related citations](#)

Select item 23689883  68.

[Translating research into licensed vaccines and validated and licensed diagnostic tests.](#)

Hill RE Jr, Foley PL, Clough NE, Ludemann LR, Murtle DC.

*Dev Biol (Basel).* 2013;135:53-8. doi: 10.1159/000259402. Epub 2013 May 14.

PMID:

23689883  
[PubMed - in process]

[Related citations](#)

Select item 23689879  69.

[The role of the department of homeland security, science and technology directorate in the development of vaccines and diagnostics for transboundary animal diseases.](#)

Colby M, Coats M, Brake D, Fine J.

*Dev Biol (Basel).* 2013;135:3-14. doi: 10.1159/000265588. Epub 2013 May 14.

**PMID:**

23689879  
[PubMed - in process]

[Related citations](#)

Select item 23689807  70.

[Health Maintenance and Vaccination Strategies in Pediatric Inflammatory Bowel Disease.](#)

Breglio KJ, Rosh JR.

Inflamm Bowel Dis. 2013 May 17. [Epub ahead of print]

**PMID:**

23689807  
[PubMed - as supplied by publisher]

[Related citations](#)

Select item 23689103  71.

[Universal hepatitis B vaccination in Belgium: impact on serological markers 3 and 7 years after implementation.](#)

Theeten H, Hutse V, Hoppenbrouwers K, Beutels P, VAN Damme P.

Epidemiol Infect. 2013 May 21:1-11. [Epub ahead of print]

**PMID:**

23689103  
[PubMed - as supplied by publisher]

[Related citations](#)

Select item 23689057  72.

[Intranasal, Liposome-Adjuvanted Cockroach Allergy Vaccines Made of Refined Major Allergen and Whole-Body Extract of Periplaneta americana.](#)

Meechan P, Tungtrongchitr A, Chaisri U, Maklon K, Indrawattana N, Chaicumpa W, Sookrung N.

Int Arch Allergy Immunol. 2013 May 14;161(4):351-362. [Epub ahead of print]

**PMID:**

23689057  
[PubMed - as supplied by publisher]

[Related citations](#)

Select item 23688547  73.

[Rotavirus genotype distribution during the pre-vaccine period in Bolivia: 2007-2008.](#)

Rivera R, Forney K, Castro MR, Rebolledo PA, Mamani N, Patzi M, Halkyer P, Leon JS, Iñiguez V.

Int J Infect Dis. 2013 May 17. doi:pii: S1201-9712(13)00145-8.  
10.1016/j.ijid.2013.03.016. [Epub ahead of print]

PMID:

23688547

[PubMed - as supplied by publisher]

[Related citations](#)

Select item 23688546  74.

[Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults.](#)

Beran JI, Peeters M, Dewé W, Raupachová J, Hobzová L, Devaster JM.

BMC Infect Dis. 2013 May 20;13(1):224. [Epub ahead of print]

PMID:

23688546

[PubMed - as supplied by publisher]

[Free Article](#)

[Related citations](#)

Select item 23688527  75.

[Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.](#)

Jackson LA, Gurtman A, Rice K, Pauksens K, Greenberg RN, Jones TR, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B.

Vaccine. 2013 May 17. doi:pii: S0264-410X(13)00588-4.  
10.1016/j.vaccine.2013.05.010. [Epub ahead of print]

PMID:

23688527

[PubMed - as supplied by publisher]

[Related citations](#)

Select item 23688526  76.

**Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults.**

Jackson LA, Gurtman A, van Cleeff M, Jansen KU, Jayawardene D, Devlin C, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B.

Vaccine. 2013 May 17. doi:pii: S0264-410X(13)00587-2.  
10.1016/j.vaccine.2013.04.085. [Epub ahead of print]

**PMID:**

**23688526**

[PubMed - as supplied by publisher]

**Related citations**

Select item 23688525  77.

**Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older.**

Jackson LA, Gurtman A, van Cleeff M, Frenck RW, Treanor J, Jansen KU, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B.

Vaccine. 2013 May 17. doi:pii: S0264-410X(13)00586-0.  
10.1016/j.vaccine.2013.04.084. [Epub ahead of print]

**PMID:**

**23688525**

[PubMed - as supplied by publisher]

**Related citations**

Select item 23688524  78.

**Seasonal influenza vaccine effectiveness in pre- and full-term children aged 6-23 months over multiple seasons.**

Shen S, Campitelli MA, Calzavara A, Guttmann A, Kwong JC.

Vaccine. 2013 May 17. doi:pii: S0264-410X(13)00589-6.  
10.1016/j.vaccine.2013.05.011. [Epub ahead of print]

**PMID:**

**23688524**

[PubMed - as supplied by publisher]

**Related citations**

Select item 23688248  79.

[\*\*Pathogenic, diagnostic and vaccine potential of leptospiral outer membrane proteins \(OMPs\).\*\*](#)

**Raja V, Natarajaseenivasan K.**

**Crit Rev Microbiol. 2013 May 21. [Epub ahead of print]**

**PMID:**

[23688248](#)  
[PubMed - as supplied by publisher]

[\*\*Related citations\*\*](#)

Select item 23688153  80.

[\*\*Immunogenicity of a Multiepitope Plasmid DNA Encoding T and B Lymphocyte Epitopes from Latent Membrane Protein 2 \(LMP2\) of Epstein-Barr Virus as a Vaccine in Mice.\*\*](#)

**Li W, Chen Q, Lin Q, Lv Y, Feng J, Liu J, Xu W, Chen S, Zhu X, Zhang L.**

**Protein Pept Lett. 2013 May 13. [Epub ahead of print]**

**PMID:**

[23688153](#)  
[PubMed - as supplied by publisher]

[\*\*Related citations\*\*](#)

Select item 23687999  81.

[\*\*Impact of 13-valent pneumococcal conjugate vaccine \(PCV13\) in a pandemic similar to the 2009 H1N1 in the United States.\*\*](#)

**McGarry LJ, Gilmore KE, Rubin JL, Klugman KP, Strutton DR, Weinstein MC.**

**BMC Infect Dis. 2013 May 21;13(1):229. [Epub ahead of print]**

**PMID:**

[23687999](#)  
[PubMed - as supplied by publisher]

[\*\*Free Article\*\*](#)

[\*\*Related citations\*\*](#)

Select item 23687584  82.

[\*\*Noroviruses: The Most Common Pediatric Viral Enteric Pathogen at a Large University Hospital After Introduction of Rotavirus Vaccination.\*\*](#)

**Koo HL, Neill FH, Estes MK, Munoz FM, Cameron A, Dupont HL, Atmar RL.**

**J Pediatric Infect Dis Soc. 2013 Mar;2(1):57-60. Epub 2012 Aug 3.**

**PMID:**

[23687584](#)  
[PubMed]

[Related citations](#)

Select item 23687580  83.

[Laboratory-Confirmed Rotavirus Disease in Utah Children: Clinical and Economic Impact of Rotavirus Vaccination.](#)

**Guerra AH, Stockmann C, Pavia AT, Hersh AL, Thorell EA, Weng HY, Korgenski K, Byington CL, Ampofo K.**

**J Pediatric Infect Dis Soc. 2012 Dec;1(4):268-277. Epub 2012 Jun 22.**

**PMID:**

[23687580](#)  
[PubMed]

[Related citations](#)

Select item 23687149  84.

[Influences of F-strain \*Mycoplasma gallisepticum\* vaccine on productive and reproductive performance of commercial parent broiler chicken breeders on a multi-age farm.](#)

**Liu JJ, Ding L, Wei JZ, Li Y.**

**Poult Sci. 2013 Jun;92(6):1535-42. doi: 10.3382/ps.2012-02999.**

**PMID:**

[23687149](#)  
[PubMed - in process]

[Related citations](#)

Select item 23687018  85.

[Influenza. Synthetic vaccine strain may speed up pandemic response.](#)

**Kupferschmidt K.**

**Science. 2013 May 17;340(6134):797. doi: 10.1126/science.340.6134.797. No abstract available.**

**PMID:**

[23687018](#)

[PubMed - in process]

[Related citations](#)

Select item 23686894  86.

[\*\*Improved Lipid Profile in Hyperlipidemic Patients Taking Vaccinium arctostaphylos Fruit Hydroalcoholic Extract: A Randomized Double-Blind Placebo-Controlled Clinical Trial.\*\*](#)

Kianbakht S, Abasi B, Hashem Dabaghian F.

*Phytother Res.* 2013 May 20. doi: 10.1002/ptr.5011. [Epub ahead of print]

**PMID:**

[23686894](#)

[PubMed - as supplied by publisher]

[Related citations](#)

Select item 23686582  87.

[\*\*Hilary Koprowski \(1916-2013\): Vaccine pioneer, art lover, and scientific leader.\*\*](#)

Croce CM.

*Proc Natl Acad Sci U S A.* 2013 May 17. [Epub ahead of print] No abstract available.

**PMID:**

[23686582](#)

[PubMed - as supplied by publisher]

[Related citations](#)

Select item 23686259  88.

[\*\*HIF-1 \$\alpha\$  influences myeloid cell antigen presentation and response to subcutaneous OVA vaccination.\*\*](#)

Bhandari T, Olson J, Johnson RS, Nizet V.

*J Mol Med (Berl).* 2013 May 19. [Epub ahead of print]

**PMID:**

[23686259](#)

[PubMed - as supplied by publisher]

[Related citations](#)

Select item 23686226  89.

[A bystander cell-based GM-CSF secreting vaccine synergizes with a low dose of cyclophosphamide and induces therapeutic immune responses against murine hepatocellular carcinoma.](#)

Chen C, Hou J, Lin Z, Yao M, Jiang R, Wang Y, Gao Y, Shao Q, Deng L, Chen Y, Sun B.

Cell Mol Immunol. 2013 May 20. doi: 10.1038/cmi.2013.20. [Epub ahead of print]

PMID:

23686226  
[PubMed - as supplied by publisher]

[Related citations](#)

Select item 23685836  90.

[Vaccination with Dendritic Cell/Tumor Fusions following Autologous Stem Cell Transplant Induces Immunologic and Clinical Responses in Multiple Myeloma Patients.](#)

Rosenblatt J, Avivi I, Vasir B, Uhl L, Munshi NC, Katz T, Dey B, Somaia P, Mills H, Campigotto F, Weller E, Joyce R, Levine J, Tzachanis D, Richardson PG, Laubach J, Raje NS, Boussiatis VA, Yuan YE, Bisharat L, Held V, Rowe JM, Anderson KC, Kufe D, Avigan DE.

Clin Cancer Res. 2013 May 17. [Epub ahead of print]

PMID:

23685836  
[PubMed - as supplied by publisher]

[Related citations](#)

Select item 23685246  91.

[Strengthening the influenza vaccine virus selection and development process: Outcome document of the 2nd WHO Informal Consultation for Improving Influenza Vaccine Virus Selection held at the Centre International de Conférences \(CICG\) Geneva, Switzerland, 7 to 9 December 2011.](#)

WHO Writing Group.

Vaccine. 2013 May 16. doi:pii: S0264-410X(13)00637-3.  
10.1016/j.vaccine.2013.05.049. [Epub ahead of print] No abstract available.

PMID:

23685246  
[PubMed - as supplied by publisher]

[Related citations](#)

Select item 23685068  92.

[\*\*The prospects and challenges of universal vaccines for influenza.\*\*](#)

**Subbarao K, Matsuoka Y.**

**Trends Microbiol. 2013 May 16. doi:pii: S0966-842X(13)00074-7.  
10.1016/j.tim.2013.04.003. [Epub ahead of print]**

**PMID:**

**23685068  
[PubMed - as supplied by publisher]**

[\*\*Related citations\*\*](#)

Select item 23684847  93.

[\*\*Comparison of initial feasibility of host cell lines for viral vaccine production.\*\*](#)

**Vlecken DH, Pelgrim RP, Ruminski S, Bakker WA, van der Pol LA.**

**J Virol Methods. 2013 May 14. doi:pii: S0166-0934(13)00175-4.  
10.1016/j.jviromet.2013.04.020. [Epub ahead of print]**

**PMID:**

**23684847  
[PubMed - as supplied by publisher]**

[\*\*Related citations\*\*](#)

Select item 23684840  94.

[\*\*Functional evaluation of malaria Pfs25 DNA vaccine by in vivo electroporation in olive baboons.\*\*](#)

**Kumar R, Nyakundi R, Kariuki T, Ozwara H, Nyamongo O, Mlambo G, Ellefsen B, Hannaman D, Kumar N.**

**Vaccine. 2013 May 15. doi:pii: S0264-410X(13)00562-8.  
10.1016/j.vaccine.2013.05.006. [Epub ahead of print]**

**PMID:**

**23684840  
[PubMed - as supplied by publisher]**

[\*\*Related citations\*\*](#)

Select item 23684838  95.

[\*\*Hepatitis B virus vaccination in children with steroid sensitive nephrotic syndrome: Immunogenicity and safety?\*\*](#)

**Yıldız N, Sever L, Kasapçopur O, Cullu F, Arısoy N, Çalışkan S.**

**Vaccine.** 2013 May 15. doi:pii: S0264-410X(13)00560-4.  
10.1016/j.vaccine.2013.05.004. [Epub ahead of print]

**PMID:**

23684838  
[PubMed - as supplied by publisher]

[Related citations](#)

Select item 23684837  96.

[Optimal targeting of seasonal influenza vaccination toward younger ages is robust to parameter uncertainty.](#)

Ndeffo Mbah ML, Medlock J, Meyers LA, Galvani AP, Townsend JP.

**Vaccine.** 2013 May 15. doi:pii: S0264-410X(13)00521-5.  
10.1016/j.vaccine.2013.04.052. [Epub ahead of print]

**PMID:**

23684837  
[PubMed - as supplied by publisher]

[Related citations](#)

Select item 23684836  97.

[Developing Countries Vaccine Manufacturers Network \(DCVMN\): Engaging to step up for vaccine discovery and access. Meeting Report 2012.](#)

Pagliusi S, Makhoana M, Datla M, Leite L, Hendriks J, Gholami A, Huang W, Gao Y, Jadhav S, Harshavardhan GV, Wu Y, Suhardono M, Homma A.

**Vaccine.** 2013 May 15. doi:pii: S0264-410X(13)00555-0.  
10.1016/j.vaccine.2013.04.082. [Epub ahead of print]

**PMID:**

23684836  
[PubMed - as supplied by publisher]

[Related citations](#)

Select item 23684835  98.

[Influences on parental acceptance of HPV vaccination in demonstration projects in Uganda and Vietnam.](#)

Galagan SR, Paul P, Menezes L, Lamontagne DS.

**Vaccine.** 2013 May 15. doi:pii: S0264-410X(13)00525-2.  
10.1016/j.vaccine.2013.04.056. [Epub ahead of print]

**PMID:**

23684835

[PubMed - as supplied by publisher]

[Related citations](#)

Select item 23684833  99.

[Evaluation of virulent and live \*Shigella sonnei\* vaccine candidates in a gnotobiotic piglet model.](#)

Jeong KI, Venkatesan MM, Barnoy S, Tzipori S.

Vaccine. 2013 May 15. doi:pii: S0264-410X(13)00549-5.  
10.1016/j.vaccine.2013.04.076. [Epub ahead of print]

**PMID:**

23684833

[PubMed - as supplied by publisher]

[Related citations](#)

Select item 23684829  100.

[Novel vaccine formulations against pertussis offer earlier onset of immunity and provide protection in the presence of maternal antibodies.](#)

Polewicz M, Gracia A, Garlapati S, van Kessel J, Strom S, Halperin SA, Hancock RE, Potter AA, Babiuk LA, Gerdts V.

Vaccine. 2013 May 15. doi:pii: S0264-410X(13)00564-1.  
10.1016/j.vaccine.2013.05.008. [Epub ahead of print]

**PMID:**

23684829

[PubMed - as supplied by publisher]

[Related citations](#)

Select item 23684828  101.

[Post-vaccination serological test results of infants at risk of perinatal transmission of hepatitis B using an intensified follow-up programme in a London centre.](#)

Tong CY, Robson C, Wu Y, Issa R, Watts T, Wilkinson M, Wong T, Lorek A.

Vaccine. 2013 May 15. doi:pii: S0264-410X(13)00556-2.  
10.1016/j.vaccine.2013.04.083. [Epub ahead of print]

**PMID:**

23684828

[PubMed - as supplied by publisher]

[Related citations](#)

Select item 23684827  102.

[\*\*Trends in compliance with two-dose influenza vaccine recommendations among children aged 6 months through 8 years.\*\*](#)

Pabst LJ, Chaves SS, Weinbaum C.

Vaccine. 2013 May 15. doi:pii: S0264-410X(13)00553-7.  
10.1016/j.vaccine.2013.04.080. [Epub ahead of print]

PMID:

**23684827**

[PubMed - as supplied by publisher]

[Related citations](#)

Select item 23684826  103.

[\*\*Epidemiology of invasive pneumococcal disease in the pre-conjugate vaccine era: South Africa, 2003-2008.\*\*](#)

**von Gottberg A, Cohen C, de Gouveia L, Meiring S, Quan V, Whitelaw A, Crowther-Gibson P, Madhi SA, Whitney CG, Klugman KP.**

Vaccine. 2013 May 15. doi:pii: S0264-410X(13)00550-1.  
10.1016/j.vaccine.2013.04.077. [Epub ahead of print]

PMID:

**23684826**

[PubMed - as supplied by publisher]

[Related citations](#)

Select item 23684825  104.

[\*\*Prevalence of chronic hepatitis B virus infection after implementation of a hepatitis B vaccination program among children in three provinces in Cambodia.\*\*](#)

Bunsoth M, Patel MK, Hennessey K, Duncan RJ, Wannemuehler K, Soeung SC.

Vaccine. 2013 May 15. doi:pii: S0264-410X(13)00565-3.  
10.1016/j.vaccine.2013.05.009. [Epub ahead of print]

PMID:

**23684825**

[PubMed - as supplied by publisher]

[Related citations](#)

Select item 23684824  105.

[Impact of pneumococcal conjugate vaccines on nasopharyngeal invasive disease among unvaccinated people: Review of evidence on indirect effects.](#)

Davis S, Deloria-Knoll M, Kassa HT, O'Brien KL.

Vaccine. 2013 May 15. doi:pii: S0264-410X(13)00561-6.  
10.1016/j.vaccine.2013.05.005. [Epub ahead of print]

**PMID:**

23684824  
[PubMed - as supplied by publisher]

[Related citations](#)

Select item 23684823  106.

[Immunogenicity and safety of pneumococcal conjugate polysaccharide and free polysaccharide vaccines alone or combined in HIV-infected adults in Brazil.](#)

Ho YL, Brandão AP, de Cunto Brandileone MC, Lopes MH.

Vaccine. 2013 May 15. doi:pii: S0264-410X(13)00534-3.  
10.1016/j.vaccine.2013.04.065. [Epub ahead of print]

**PMID:**

23684823  
[PubMed - as supplied by publisher]

[Related citations](#)

Select item 23684631  107.

[Sequence and phylogenetic analyses of human rotavirus strains: Comparison of VP7 and VP8\\* antigenic epitopes between Tunisian and vaccine strains before national rotavirus vaccine introduction.](#)

Fredj MB, Benhamida-Rebaï M, Heylen E, Zeller M, Moussa A, Kacem S, Van Ranst M, Matthijnssens J, Trabelsi A.

Infect Genet Evol. 2013 May 15. doi:pii: S1567-1348(13)00193-7.  
10.1016/j.meegid.2013.05.008. [Epub ahead of print]

**PMID:**

23684631  
[PubMed - as supplied by publisher]

[Related citations](#)

Select item 23684067  108.

[C3a receptor promotes viral containment in mice inoculated with vaccinia virus at sites of allergic skin inflammation.](#)

Kumar L, Lu B, Gerard C, Geha RS.

J Allergy Clin Immunol. 2013 May 16. doi:pii: S0091-6749(13)00530-7.  
10.1016/j.jaci.2013.03.041. [Epub ahead of print] No abstract available.

PMID:

23684067

[PubMed - as supplied by publisher]

[Related citations](#)

Select item 23683999  109.

[Evaluation of the immune response elicited by vaccination with viral vectors encoding FMDV capsid proteins and boosted with inactivated virus.](#)

Romanutti C, D'Antuono A, Palacios C, Quattrocchi V, Zamorano P, La Torre J, Mattion N.

Vet Microbiol. 2013 Apr 23. doi:pii: S0378-1135(13)00220-4.  
10.1016/j.vetmic.2013.04.017. [Epub ahead of print]

PMID:

23683999

[PubMed - as supplied by publisher]

[Related citations](#)

Select item 23683613  110.

[GAVI injects new life into HPV vaccine rollout.](#)

[No authors listed]

Lancet. 2013 May 18;381(9879):1688. doi: 10.1016/S0140-6736(13)61058-2. No abstract available.

PMID:

23683613

[PubMed - in process]

[Related citations](#)

Select item 23683024  111.

[Immunity in heifers 12 months after vaccination with a multivalent vaccine containing a United States \*Leptospira borgpetersenii\* serovar Hardjo isolate.](#)

**Zimmerman AD, Springer EW, Barling KS, Buterbaugh RE, Pooley RD, Scholz DA, Rhoades JR, Chase CC.**

**J Am Vet Med Assoc. 2013 Jun 1;242(11):1573-7. doi: 10.2460/javma.242.11.1573.**

**PMID:**

[23683024](#)  
[PubMed - in process]

[Related citations](#)

Select item 23683023  112.

[Effect of a monovalent vaccine against \*Leptospira borgpetersenii\* serovar Hardjo strain hardjobovis on fertility in Holstein dairy cattle.](#)

**Plunkett AH, Graham TW, Famula TR, Oberbauer AM.**

**J Am Vet Med Assoc. 2013 Jun 1;242(11):1564-72. doi: 10.2460/javma.242.11.1564.**

**PMID:**

[23683023](#)  
[PubMed - in process]

[Related citations](#)

Select item 23682824  113.

[Cellular and molecular chaperone fusion vaccines: Targeting resistant cancer cell populations.](#)

**Calderwood SK, Gong J, Stevenson MA, Murshid A.**

**Int J Hyperthermia. 2013 May 17. [Epub ahead of print]**

**PMID:**

[23682824](#)  
[PubMed - as supplied by publisher]

[Related citations](#)

Select item 23682741  114.

[Acetobacter strains isolated during the acetification of blueberry \(\*Vaccinium corymbosum\* L.\) wine.](#)

**Hidalgo C, García D, Romero J, Mas A, Torija MJ, Mateo E.**

PMID:

23682741  
[PubMed - as supplied by publisher]

[Related citations](#)

Select item 23682516  115.

[Efficacy of the trivalent influenza vaccination in Thai patients with hemodialysis or kidney transplant compared with healthy volunteers.](#)

Krairittichai U, Chittaganpitch M.

J Med Assoc Thai. 2013 Mar;96 Suppl 3:S1-7.

PMID:

23682516  
[PubMed - in process]

[Related citations](#)

Select item 23682456  116.

[Recurrent respiratory papillomatosis: A possible role for the HPV vaccine?](#)

Lively JM, Shah RK.

JAAPA. 2013 May;26(5):48, 51-3. No abstract available.

PMID:

23682456  
[PubMed - in process]

[Related citations](#)

Select item 23682379  117.

[First candidate HIV vaccine to employ Sendai vector poised for trials.](#)

McEnery R.

IAVI Rep. 2013 Spring;17(1):18. No abstract available.

PMID:

23682379  
[PubMed - in process]

[Related citations](#)

Select item 23682040  118.

[Influenza: marketing vaccine by marketing disease.](#)

Doshi P.

BMJ. 2013 May 16;346:f3037. doi: 10.1136/bmj.f3037. No abstract available.

PMID:

23682040  
[PubMed - in process]

[Related citations](#)

Select item 23682005  119.

[Does vaccine dose predict response to the monovalent pandemic H1N1 influenza a vaccine in children with acute lymphoblastic leukemia? A single-centre study.](#)

Leahy TR, Smith OP, Bacon CL, Storey L, Lynam P, Gavin PJ, Butler KM, O'Marcaigh AS.

Pediatr Blood Cancer. 2013 May 16. doi: 10.1002/pbc.24589. [Epub ahead of print]

PMID:

23682005  
[PubMed - as supplied by publisher]

[Related citations](#)

Select item 23681435  120.

[Vaccinating HIV Patients: Focus on Human Papillomavirus and Herpes Zoster Vaccines.](#)

Koenig HC, Garland JM, Weissman D, Mounzer K.

AIDS Rev. 2013 May 17;15(2):77-86. [Epub ahead of print]

PMID:

23681435  
[PubMed - as supplied by publisher]

[Related citations](#)

Select item 23681316  121.

[Vaccination Perceptions and Barriers of School Employees: A Pilot Study.](#)

Luthy KE, Houle K, Beckstrand RL, Macintosh J, Lakin RG.

J Sch Nurs. 2013 May 16. [Epub ahead of print]

PMID:

23681316

[PubMed - as supplied by publisher]

[Related citations](#)

Select item 23680442  122.

[\*\*Distribution of carried pneumococcal clones in UK children following the introduction of the 7-valent pneumococcal conjugate vaccine: A 3-year cross-sectional population based analysis.\*\*](#)

Tocheva AS, Jefferies JM, Christodoulides M, Faust SN, Clarke SC.

Vaccine. 2013 May 13. doi:pii: S0264-410X(13)00544-6.  
10.1016/j.vaccine.2013.04.075. [Epub ahead of print]

PMID:

23680442

[PubMed - as supplied by publisher]

[Related citations](#)

Select item 23680441  123.

[\*\*High-dose vitamin A supplementation administered with vaccinations after 6 months of age: Sex-differential adverse reactions and morbidity.\*\*](#)

Fisker AB, Bale C, Jørgensen MJ, Balde I, Hornshøj L, Bibby BM, Aaby P, Benn CS.

Vaccine. 2013 May 13. doi:pii: S0264-410X(13)00541-0.  
10.1016/j.vaccine.2013.04.072. [Epub ahead of print]

PMID:

23680441

[PubMed - as supplied by publisher]

[Related citations](#)

Select item 23680440  124.

[\*\*Changes in Streptococcus pneumoniae serotype distribution in invasive disease and nasopharyngeal carriage after the heptavalent pneumococcal conjugate vaccine introduction in Bogotá, Colombia.\*\*](#)

Parra EL, Hoz FD, Díaz PL, Sanabria O, Realpe ME, Moreno JE.

Vaccine. 2013 May 13. doi:pii: S0264-410X(13)00543-4.  
10.1016/j.vaccine.2013.04.074. [Epub ahead of print]

**PMID:**

23680440

[PubMed - as supplied by publisher]

[Related citations](#)

Select item 23680137  125.

[\[Travel queries in an international vaccination center.\]](#)

**Muñoz-Cidat TM, Mateos-Conde J, González-Pérez LC, Aránzazu García-Iglesias M.**

Gac Sanit. 2013 May 13. doi:pii: S0213-9111(13)00079-4.

10.1016/j.gaceta.2013.04.001. [Epub ahead of print] Spanish. No abstract available.

**PMID:**

23680137

[PubMed - as supplied by publisher]

[Free Article](#)

[Related citations](#)

Select item 23680130  126.

[A small jab - a big effect: nonspecific immunomodulation by vaccines.](#)

**Benn CS, Netea MG, Selin LK, Aaby P.**

Trends Immunol. 2013 May 13. doi:pii: S1471-4906(13)00058-6.

10.1016/j.it.2013.04.004. [Epub ahead of print]

**PMID:**

23680130

[PubMed - as supplied by publisher]

[Related citations](#)

Select item 23680109  127.

[Mycoplasma hyopneumoniae: From disease to vaccine development.](#)

**Simionatto S, Marchioro SB, Maes D, Dellagostin OA.**

Vet Microbiol. 2013 Apr 24. doi:pii: S0378-1135(13)00235-6.

10.1016/j.vetmic.2013.04.019. [Epub ahead of print]

**PMID:**

23680109

[PubMed - as supplied by publisher]

[Related citations](#)

Select item 23679337  128.

[ESAT-6-gpi DNA vaccine augmented the specific antitumor efficacy induced by the tumor vaccine B16F10-ESAT-6-gpi/IL-21 in a mouse model.](#)

He X, Wang J, Zhao F, Chen D, Chen J, Zhang H, Yang C, Liu Y, Dou J.

Scand J Immunol. 2013 May 17. doi: 10.1111/sji.12074. [Epub ahead of print]

PMID:

23679337  
[PubMed - as supplied by publisher]

[Related citations](#)

Select item 23678935  129.

[Timeliness of Pediatric Influenza Vaccination Compared With Seasonal Influenza Activity in an Urban Community, 2004-2008.](#)

Hofstetter AM, Natarajan K, Rabinowitz D, Martinez RA, Vawdrey D, Arpadi S, Stockwell MS.

Am J Public Health. 2013 May 16. [Epub ahead of print]

PMID:

23678935  
[PubMed - as supplied by publisher]

[Related citations](#)

Select item 23678735  130.

[Construction of an attenuated Salmonella delivery system harboring genes encoding various virulence factors of avian pathogenic Escherichia coli and its potential as a candidate vaccine for chicken colibacillosis.](#)

Chaudhari AA, Matsuda K, Lee JH.

Avian Dis. 2013 Mar;57(1):88-96.

PMID:

23678735  
[PubMed - in process]

[Related citations](#)

Select item 23678734  131.

[H9N2 avian influenza virus-induced conjunctivitis model for vaccine efficacy testing.](#)

**Kim IH, Kwon HJ, Kimabce JH.**

**Avian Dis. 2013 Mar;57(1):83-7.**

**PMID:**

**23678734**  
[PubMed - in process]

**Related citations**

Select item 23678728  132.

[\*\*Multivalent virus-like-particle vaccine protects against classic and variant infectious bursal disease viruses.\*\*](#)

**Jackwood DJ.**

**Avian Dis. 2013 Mar;57(1):41-50.**

**PMID:**

**23678728**  
[PubMed - in process]

**Related citations**

Select item 23678726  133.

[\*\*Safety and efficacy of a metabolic drift live attenuated \*Salmonella Gallinarum\* vaccine against fowl typhoid.\*\*](#)

**Shehata AA, Sultan H, Hafez HM, Krüger M.**

**Avian Dis. 2013 Mar;57(1):29-35.**

**PMID:**

**23678726**  
[PubMed - in process]

**Related citations**

Select item 23678724  134.

[\*\*Molecular characterization of contaminating infectious anemia virus of chickens in live commercial vaccines produced in the 1990s.\*\*](#)

**Marin SY, Barrios PR, Rios RL, Resende M, Resende JS, Santos BM, Martinsa NR.**

**Avian Dis. 2013 Mar;57(1):15-21.**

**PMID:**

**23678724**

[PubMed - in process]

Related citations

Select item 23678682  135.

Vaccinate boys with the HPV vaccine? Really?

Thomas TL, Snell S.

J Spec Pediatr Nurs. 2013 Apr;18(2):165-9. No abstract available.

PMID:

23678682

[PubMed - in process]

Related citations

**AMEDEO - Vaccines Publicaciones (20 - 05 - 2013): 29 artículos nuevos.**

Vacunas meningococo (*Neisseria meningitidis*)

17. POELLABAUER EM, Pavlova BG, Fritsch S, Singer J, et al.

Single priming dose of meningococcal group C conjugate vaccine (NeisVac-C) in infants.

Vaccine. 2013 May 11. pii: S0264-410X(13)00539.

PubMed: [www.amedeo.com/p2.php?id=23672977&s=vac&pm=badc2a9eebb0fad](http://www.amedeo.com/p2.php?id=23672977&s=vac&pm=badc2a9eebb0fad)

ABSTRACT available

Share: <http://m.amedeo.com/23672977>

Vacunas neumococo (*Streptococcus pneumoniae*)

27. HANNA-WAKIM R, Chehab H, Mahfouz I, Nassar F, et al.

Epidemiologic characteristics, serotypes, and antimicrobial susceptibilities of invasive *Streptococcus pneumoniae* isolates in a nationwide surveillance study in Lebanon.

Vaccine. 2012;30 Suppl 6:G11-7.

PubMed: [www.amedeo.com/p2.php?id=23228352&s=vac&pm=badc2a9eebb0fad](http://www.amedeo.com/p2.php?id=23228352&s=vac&pm=badc2a9eebb0fad)

ABSTRACT available

Share: <http://m.amedeo.com/23228352>

Vacunas fiebre tifoidea (*Salmonella typhi*)

20. KALJEE LM, Pach A, Thriemer K, Ley B, et al.

Desirability for a typhoid fever vaccine among rural residents, Pemba Island, Tanzania.

Vaccine. 2013 May 9. pii: S0264-410X(13)00527.

PubMed: [www.amedeo.com/p2.php?id=23664993&s=vac&pm=badc2a9eebb0fad](http://www.amedeo.com/p2.php?id=23664993&s=vac&pm=badc2a9eebb0fad)

ABSTRACT available

Share: <http://m.amedeo.com/23664993>

Vacuna tuberculosis (*Mycobacterium tuberculosis*)

12. BALETA A.

Profile: SATVI-a leading light in tuberculosis vaccine research.

**Lancet.** 2013;381:984.

PubMed: [www.amedeo.com/p2.php?id=23668568&s=vac&pm=badc2a9eebb0fad](http://www.amedeo.com/p2.php?id=23668568&s=vac&pm=badc2a9eebb0fad)

Share: <http://m.amedeo.com/23668568>

### **Vacunas, otras**

**1. WALDENLIND L, Grundmark B, Azarbayjani F, Borjesson A, et al.**

**Is the risk of narcolepsy also increased with non-adjuvanted flu vaccines?**  
**BMJ.** 2013;346:f2769.

PubMed: [www.amedeo.com/p2.php?id=23670343&s=vac&pm=badc2a9eebb0fad](http://www.amedeo.com/p2.php?id=23670343&s=vac&pm=badc2a9eebb0fad)

Share: <http://m.amedeo.com/23670343>

**2. DYER O.**

**Ontario excludes thousands of children from schools for lack of vaccination.**  
**BMJ.** 2013;346:f3068.

PubMed: [www.amedeo.com/p2.php?id=23667130&s=vac&pm=badc2a9eebb0fad](http://www.amedeo.com/p2.php?id=23667130&s=vac&pm=badc2a9eebb0fad)

Share: <http://m.amedeo.com/23667130>

**3. GULLAND A.**

**Drug companies agree to cut price of HPV vaccine to developing countries to increase accessibility.**

**BMJ.** 2013;346:f3025.

PubMed: [www.amedeo.com/p2.php?id=23667128&s=vac&pm=badc2a9eebb0fad](http://www.amedeo.com/p2.php?id=23667128&s=vac&pm=badc2a9eebb0fad)

Share: <http://m.amedeo.com/23667128>

**4. KAHN JA, Xu J, Kapogiannis BG, Rudy B, et al.**

**Immunogenicity and Safety of the Human Papillomavirus-6, -11, -16, -18 Vaccine in HIV-Infected Young Women.**

**Clin Infect Dis.** 2013.

PubMed: [www.amedeo.com/p2.php?id=23667266&s=vac&pm=badc2a9eebb0fad](http://www.amedeo.com/p2.php?id=23667266&s=vac&pm=badc2a9eebb0fad)

**ABSTRACT available**

Share: <http://m.amedeo.com/23667266>

**5. YIN L, Calvo-Calle JM, Cruz J, Newman FK, et al.**

**CD4+ T Cells Provide Intermolecular Help To Generate Robust Antibody Responses in Vaccinia Virus-Vaccinated Humans.**

**J Immunol.** 2013.

PubMed: [www.amedeo.com/p2.php?id=23667112&s=vac&pm=badc2a9eebb0fad](http://www.amedeo.com/p2.php?id=23667112&s=vac&pm=badc2a9eebb0fad)

**ABSTRACT available**

Share: <http://m.amedeo.com/23667112>

**6. WAAIJENBORG S, Hahne SJ, Mollema L, Smits GP, et al.**

**Waning of Maternal Antibodies Against Measles, Mumps, Rubella, and Varicella in Communities With Contrasting Vaccination Coverage.**

**J Infect Dis.** 2013.

PubMed: [www.amedeo.com/p2.php?id=23661802&s=vac&pm=badc2a9eebb0fad](http://www.amedeo.com/p2.php?id=23661802&s=vac&pm=badc2a9eebb0fad)

**ABSTRACT available**

Share: <http://m.amedeo.com/23661802>

**7. GANS HA, Maldonado YA.**

**Loss of Passively Acquired Maternal Antibodies in Highly Vaccinated Populations: An Emerging Need to Define the Ontogeny of Infant Immune Responses.**  
J Infect Dis. 2013.

PubMed: [www.amedeo.com/p2.php?id=23661801&s=vac&pm=badc2a9eebb0fad](http://www.amedeo.com/p2.php?id=23661801&s=vac&pm=badc2a9eebb0fad)

Share: <http://m.amedeo.com/23661801>

**8. TROY SB, Musingwini G, Halpern MS, Huang C, et al.**  
Vaccine Poliovirus Shedding and Immune Response to Oral Polio Vaccine in HIV-Infected and Uninfected Zimbabwean Infants.  
J Infect Dis. 2013.

PubMed: [www.amedeo.com/p2.php?id=23661792&s=vac&pm=badc2a9eebb0fad](http://www.amedeo.com/p2.php?id=23661792&s=vac&pm=badc2a9eebb0fad)  
ABSTRACT available

Share: <http://m.amedeo.com/23661792>

**9. MENG X, Wu X, Yan B, Deng J, et al.**  
Analysis of the role of vaccinia virus H7 in virion membrane biogenesis with a H7-deletion mutant.  
J Virol. 2013.

PubMed: [www.amedeo.com/p2.php?id=23678177&s=vac&pm=badc2a9eebb0fad](http://www.amedeo.com/p2.php?id=23678177&s=vac&pm=badc2a9eebb0fad)

ABSTRACT available

Share: <http://m.amedeo.com/23678177>

**10. SHIVAKOTI R, Siwek M, Hauer D, Schultz KL, et al.**  
INDUCTION OF DENDRITIC CELL PRODUCTION OF TYPE I AND TYPE III INTERFERONS BY WILD-TYPE AND VACCINE STRAINS OF MEASLES VIRUS: ROLE OF DEFECTIVE INTERFERING RNAs.  
J Virol. 2013.

PubMed: [www.amedeo.com/p2.php?id=23678166&s=vac&pm=badc2a9eebb0fad](http://www.amedeo.com/p2.php?id=23678166&s=vac&pm=badc2a9eebb0fad)

ABSTRACT available

Share: <http://m.amedeo.com/23678166>

**11. MARGINE I, Hai R, Albrecht RA, Obermoser G, et al.**  
H3N2 influenza virus infection induces broadly reactive hemagglutinin stalk antibodies in humans and mice.  
J Virol. 2013.

PubMed: [www.amedeo.com/p2.php?id=23408625&s=vac&pm=badc2a9eebb0fad](http://www.amedeo.com/p2.php?id=23408625&s=vac&pm=badc2a9eebb0fad)

ABSTRACT available

Share: <http://m.amedeo.com/23408625>

**12. BALETA A.**  
Profile: SATVI-a leading light in tuberculosis vaccine research.  
Lancet. 2013;381:984.

PubMed: [www.amedeo.com/p2.php?id=23668568&s=vac&pm=badc2a9eebb0fad](http://www.amedeo.com/p2.php?id=23668568&s=vac&pm=badc2a9eebb0fad)

Share: <http://m.amedeo.com/23668568>

**13. PALLANSCH MA, Oberste MS.**  
Enterovirus 71 encephalitis: a new vaccine on the horizon?  
Lancet. 2013;381:976-7.

PubMed: [www.amedeo.com/p2.php?id=23668563&s=vac&pm=badc2a9eebb0fad](http://www.amedeo.com/p2.php?id=23668563&s=vac&pm=badc2a9eebb0fad)

Share: <http://m.amedeo.com/23668563>

**14. HABER P, Patel M, Pan Y, Baggs J, et al.**

Intussusception After Rotavirus Vaccines Reported to US VAERS, 2006-2012.

Pediatrics. 2013.

PubMed: [www.amedeo.com/p2.php?id=23669521&s=vac&pm=badc2a9eebb0fad](http://www.amedeo.com/p2.php?id=23669521&s=vac&pm=badc2a9eebb0fad)  
ABSTRACT available

Share: <http://m.amedeo.com/23669521>

**15. COHEN J.**

AIDS research. More woes for struggling HIV vaccine field.

Science. 2013;340:667.

PubMed: [www.amedeo.com/p2.php?id=23661729&s=vac&pm=badc2a9eebb0fad](http://www.amedeo.com/p2.php?id=23661729&s=vac&pm=badc2a9eebb0fad)

Share: <http://m.amedeo.com/23661729>

**16. Proceedings of the Fourth ESWI Influenza Conference, September 11-14, 2011, Malta.**

Vaccine. 2012;30:7343-438.

PubMed: [www.amedeo.com/p2.php?id=23675592&s=vac&pm=badc2a9eebb0fad](http://www.amedeo.com/p2.php?id=23675592&s=vac&pm=badc2a9eebb0fad)

Share: <http://m.amedeo.com/23675592>

**17. POELLABAUER EM, Pavlova BG, Fritsch S, Singer J, et al.**

Single priming dose of meningococcal group C conjugate vaccine (NeisVac-C) in infants.

Vaccine. 2013 May 11. pii: S0264-410X(13)00539.

PubMed: [www.amedeo.com/p2.php?id=23672977&s=vac&pm=badc2a9eebb0fad](http://www.amedeo.com/p2.php?id=23672977&s=vac&pm=badc2a9eebb0fad)  
ABSTRACT available

Share: <http://m.amedeo.com/23672977>

**18. CUI X, Cao Z, Sen G, Chattopadhyay G, et al.**

A novel tetrameric gp350 as a potential Epstein-Barr virus vaccine.

Vaccine. 2013 May 8. pii: S0264-410X(13)00540.

PubMed: [www.amedeo.com/p2.php?id=23665339&s=vac&pm=badc2a9eebb0fad](http://www.amedeo.com/p2.php?id=23665339&s=vac&pm=badc2a9eebb0fad)

ABSTRACT available

Share: <http://m.amedeo.com/23665339>

**19. SEMPERE L, Almenta I, Barrenengoa J, Gutierrez A, et al.**

Factors predicting response to hepatitis B vaccination in patients with inflammatory bowel disease.

Vaccine. 2013 May 9. pii: S0264-410X(13)00528.

PubMed: [www.amedeo.com/p2.php?id=23664999&s=vac&pm=badc2a9eebb0fad](http://www.amedeo.com/p2.php?id=23664999&s=vac&pm=badc2a9eebb0fad)

ABSTRACT available

Share: <http://m.amedeo.com/23664999>

**20. KALJEE LM, Pach A, Thriemer K, Ley B, et al.**

Desirability for a typhoid fever vaccine among rural residents, Pemba Island, Tanzania.

Vaccine. 2013 May 9. pii: S0264-410X(13)00527.

PubMed: [www.amedeo.com/p2.php?id=23664993&s=vac&pm=badc2a9eebb0fad](http://www.amedeo.com/p2.php?id=23664993&s=vac&pm=badc2a9eebb0fad)

**ABSTRACT available**

Share: <http://m.amedeo.com/23664993>

**21. CHESSON HW, Flagg EW, Koutsky L, Hsu K, et al.**

**Modeling the impact of quadrivalent HPV vaccination on the incidence of Pap test abnormalities in the United States.**

**Vaccine. 2013 May 9. pii: S0264-410X(13)00520.**

**PubMed: [www.amedeo.com/p2.php?id=23664991&s=vac&pm=badc2a9eebb0fad](http://www.amedeo.com/p2.php?id=23664991&s=vac&pm=badc2a9eebb0fad)**

**ABSTRACT available**

Share: <http://m.amedeo.com/23664991>

**22. REITER PL, Katz ML, Paskett ED.**

**Correlates of HPV vaccination among adolescent females from Appalachia and reasons why their parents do not intend to vaccinate.**

**Vaccine. 2013 May 9. pii: S0264-410X(13)00537.**

**PubMed: [www.amedeo.com/p2.php?id=23664990&s=vac&pm=badc2a9eebb0fad](http://www.amedeo.com/p2.php?id=23664990&s=vac&pm=badc2a9eebb0fad)**

**ABSTRACT available**

Share: <http://m.amedeo.com/23664990>

**23. LUO M, Capina R, Daniuk C, Tuff J, et al.**

**Immunogenicity of sequences around HIV-1 protease cleavage sites: Potential targets and population coverage analysis for a HIV vaccine targeting protease cleavage sites.**

**Vaccine. 2013 May 9. pii: S0264-410X(13)00526.**

**PubMed: [www.amedeo.com/p2.php?id=23664989&s=vac&pm=badc2a9eebb0fad](http://www.amedeo.com/p2.php?id=23664989&s=vac&pm=badc2a9eebb0fad)**

**ABSTRACT available**

Share: <http://m.amedeo.com/23664989>

**24. O'CONNOR AC, Kennedy ED, Loomis RJ, Haque SN, et al.**

**Prospective cost-benefit analysis of a two-dimensional barcode for vaccine production, clinical documentation, and public health reporting and tracking.**

**Vaccine. 2013 May 8. pii: S0264-410X(13)00542.**

**PubMed: [www.amedeo.com/p2.php?id=23664988&s=vac&pm=badc2a9eebb0fad](http://www.amedeo.com/p2.php?id=23664988&s=vac&pm=badc2a9eebb0fad)**

**ABSTRACT available**

Share: <http://m.amedeo.com/23664988>

**25. FREY SE, Winokur PL, Salata RA, El-Kamary SS, et al.**

**Safety and immunogenicity of IMVAMUNE smallpox vaccine using different strategies for a post event scenario.**

**Vaccine. 2013 May 9. pii: S0264-410X(13)00518.**

**PubMed: [www.amedeo.com/p2.php?id=23664987&s=vac&pm=badc2a9eebb0fad](http://www.amedeo.com/p2.php?id=23664987&s=vac&pm=badc2a9eebb0fad)**

**ABSTRACT available**

Share: <http://m.amedeo.com/23664987>

**26. MIRANDA KL, Poester FP, Minharro S, Dorneles EM, et al.**

**Evaluation of Brucella abortus S19 vaccines commercialized in Brazil:**

**Immunogenicity, residual virulence and MLVA15 genotyping.**

**Vaccine. 2013 May 9. pii: S0264-410X(13)00523.**

**PubMed: [www.amedeo.com/p2.php?id=23664986&s=vac&pm=badc2a9eebb0fad](http://www.amedeo.com/p2.php?id=23664986&s=vac&pm=badc2a9eebb0fad)**

**ABSTRACT available**

Share: <http://m.amedeo.com/23664986>

**27. HANNA-WAKIM R, Chehab H, Mahfouz I, Nassar F, et al.**  
Epidemiologic characteristics, serotypes, and antimicrobial susceptibilities of invasive *Streptococcus pneumoniae* isolates in a nationwide surveillance study in Lebanon.

Vaccine. 2012;30 Suppl 6:G11-7.

PubMed: [www.amedeo.com/p2.php?id=23228352&s=vac&pm=badc2a9eebb0fad](http://www.amedeo.com/p2.php?id=23228352&s=vac&pm=badc2a9eebb0fad)  
ABSTRACT available

Share: <http://m.amedeo.com/23228352>

**28. Should we prevent and treat seasonal influenza and how?**

Vaccine. 2012;30:7423-5.

PubMed: [www.amedeo.com/p2.php?id=23330162&s=vac&pm=badc2a9eebb0fad](http://www.amedeo.com/p2.php?id=23330162&s=vac&pm=badc2a9eebb0fad)

Share: <http://m.amedeo.com/23330162>

**29. GESSNER BD, Sanou O, Drabo A, Tamekloe TA, et al.**  
Pneumococcal serotype distribution among meningitis cases from Togo and Burkina Faso during 2007-2009.

Vaccine. 2012;30 Suppl 6:G41-5.

PubMed: [www.amedeo.com/p2.php?id=23228357&s=vac&pm=badc2a9eebb0fad](http://www.amedeo.com/p2.php?id=23228357&s=vac&pm=badc2a9eebb0fad)

ABSTRACT available

Share: <http://m.amedeo.com/23228357>

## PATENTES

**United States Patent and Trademark Office (USPTO)**

**Estrategia de búsqueda “vaccine” en título y abstract**

**(ABST/vaccine AND ISD/20130515->20130524): 10 patentes recuperadas.**

**Vacunas fiebre tifoidea (*Salmonella typhi*)**

3 [8,444,999](#)      [Mutated \*Salmonella typhi\* strain and use thereof in a vaccine](#)

**Vacunas, otras**

PAT. NO.	Title
1	<a href="#">8,445,658</a> <a href="#">Proteins with repetitive bacterial-Ig-like (Big) domains present in <i>Leptospira</i> species</a>
2	<a href="#">8,445,268</a> <a href="#">Her-2/neu DNA vaccine having anti-cancer activity</a>
3	<a href="#">8,444,999</a> <a href="#">Mutated <i>Salmonella typhi</i> strain and use thereof in a vaccine</a>
4	<a href="#">8,444,997</a> <a href="#">Methods of vaccine administration, new feline caliciviruses, and treatments for immunizing animals against feline paraovirus and feline herpes virus</a>

- |    |                                  |   |
|----|----------------------------------|---|
| 5  | <a href="#"><u>8,444,994</u></a> | <a href="#"><u>Multivalent antihelminthic vaccine</u></a>   |
| 6  | <a href="#"><u>8,444,993</u></a> | <a href="#"><u>Multi-phase emulsions based on amphiphilic block copolymers</u></a>                              |
| 7  | <a href="#"><u>8,444,991</u></a> | <a href="#"><u>Method of preparing an immunologically-active adjuvant-bound dried vaccine composition</u></a>   |
| 8  | <a href="#"><u>8,444,989</u></a> | <a href="#"><u>One dose vaccination against mycoplasma infections of pigs</u></a>                               |
| 9  | <a href="#"><u>8,444,985</u></a> | <a href="#"><u>Vaccine compositions and methods for treatment of mucormycosis and other fungal diseases</u></a> |
| 10 | <a href="#"><u>8,444,982</u></a> | <a href="#"><u>Anti-IGF-IR antibodies and uses thereof</u></a>  |

**European Patent Office (EPO)**

**Acumulado entre el 15 y el 24 de mayo de 2013: patentes recuperadas**

**Vacunas neumococo (*Streptococcus pneumoniae*)**

16. [VACCINE AGAINST STREPTOCOCCAL INFECTIONS BASED ON RECOMBINANT PROTEINS](#)

Publication info: EP2590994 (A1) 2013-05-15

**Vacunas, otras**

1. [STAPHYLOCOCCUS AUREUS SURFACE PROTEIN SA1789 AND PROTECTIVE VACCINE BASED THEREON](#)

Publication info: EP2593133 (A1) 2013-05-22

2. [PROTECTIVE VACCINE BASED ON STAPHYLOCOCCUS AUREUS PROTEIN SA2412](#)

Publication info: EP2593134 (A1) 2013-05-22

3. [MODIFIED VIRAL STRAINS, AND METHOD FOR IMPROVING THE PRODUCTION OF VACCINE SEEDS OF THE INFLUENZA VIRUS](#)

Publication info: EP2593135 (A1) 2013-05-22

4. [DNA VACCINE FOR ALZHEIMER'S DISEASE](#)

Publication info: US2013122026 (A1) 2013-05-16

5. [ATTENUATED EHRLICHIOSIS VACCINE](#)

Publication info: US2013122041 (A1) 2013-05-16

6. FERMENTATION MEDIA FREE OF ANIMAL-DERIVED COMPONENTS FOR PRODUCTION OF DIPHTHERIA TOXOIDS SUITABLE FOR HUMAN VACCINE USE

Publication info: US2013122040 (A1) 2013-05-16

7. Live Vaccine Strain

Publication info: US2013122573 (A1) 2013-05-16

8. RECOMBINANT NANOPARTICLE RSV F VACCINE FOR RESPIRATORY SYNCYTIAL VIRUS

Publication info: US2013122032 (A1) 2013-05-16

9. FIMH VACCINE AGAINST URINARY TRACT INFECTIONS (UTI)

Publication info: US2013122033 (A1) 2013-05-16

10. CANCER VACCINE

Publication info: US2013122029 (A1) 2013-05-16

11. Cross-Protective Influenza Vaccine

Publication info: US2013122045 (A1) 2013-05-16

12. NOVEL VACCINE THAT TARGETS TUMOR VESSELS AS AN EFFICIENT TOOL IN TUMOR THERAPY

Publication info: US2013122028 (A1) 2013-05-16

13. VACCINE FOR TUMOR IMMUNOTHERAPY

Publication info: WO2013068406 (A1) 2013-05-16

14. FACILITATOR-DNA COMBINATION VACCINE

Publication info: WO2013067652 (A1) 2013-05-16

15. CANCER PEPTIDE VACCINE

Publication info: EP2591799 (A1) 2013-05-15

16. VACCINE AGAINST STREPTOCOCCAL INFECTIONS BASED ON RECOMBINANT PROTEINS

Publication info: EP2590994 (A1) 2013-05-15

17. [VACCINE COMPOSITIONS BASED ON STICHOLYSIN ENCAPSULATED IN LIPOSOMES](#)

Publication info: EP2591802 (A1) 2013-05-15

18. [A RECOMBINANT VACCINE AGAINST CLOSTRIDIUM PERFRINGENS INFECTION AND EPSILON \(e \) TOXIN INTOXICATION](#)

Publication info: EP2591108 (A1) 2013-05-15

19. [Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use](#)

Publication info: EP2592137 (A1) 2013-05-15

20. [DESIGNER PEPTIDE-BASED PCV2 VACCINE](#)

Publication info: EP2590673 (A1) 2013-05-15

## TABLAS DE CONTENIDO

### Revista Vaccine

#### **Tabla de Contenidos. [New Articles in Press, 14 May-20 May 2013.](#)**

1. [Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults](#) Original Research Article

*Available online 18 May 2013*

Lisa A. Jackson, Alejandra Gurtman, Martin van Cleeff, Kathrin U. Jansen, Deepthi Jayawardene, Carmel Devlin, Daniel A. Scott, Emilio A. Emini, William C. Gruber, Beate Schmoele-Thoma

2. [Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine](#) Original Research Article

*Available online 18 May 2013*

Lisa A. Jackson, Alejandra Gurtman, Kathryn Rice, Karlis Pauksens, Richard N. Greenberg, Thomas R. Jones, Daniel A. Scott, Emilio A. Emini, William C. Gruber, Beate Schmoele-Thoma

3. [Seasonal influenza vaccine effectiveness in pre- and full-term children aged 6–23 months over multiple seasons](#)

*Available online 18 May 2013*

Shixin Shen, Michael A. Campitelli, Andrew Calzavara, Astrid Guttmann,

**Jeffrey C. Kwong**

4. **Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older** Original Research Article

**Available online 18 May 2013**  
Lisa A. Jackson, Alejandra Gurtman, Martin van Cleeff, Robert W. Frenck, John Treanor, Kathrin U. Jansen, Daniel A. Scott, Emilio A. Emini, William C. Gruber, Beate Schmoele-Thoma
5. **Strengthening the influenza vaccine virus selection and development process: Outcome document of the 2nd WHO Informal Consultation for Improving Influenza Vaccine Virus Selection held at the Centre International de Conférences (CICG) Geneva, Switzerland, 7 to 9 December 2011**

**Available online 17 May 2013**  
WHO Writing Group
6. **WHO Strategic Advisory Group of Experts (SAGE) on immunization: Request for nominations**

**Available online 16 May 2013**
7. **Epidemiology of invasive pneumococcal disease in the pre-conjugate vaccine era: South Africa, 2003–2008** Original Research Article

**Available online 16 May 2013**  
Anne von Gottberg, Cheryl Cohen, Linda de Gouveia, Susan Meiring, Vanessa Quan, Andrew Whitelaw, Penny Crowther-Gibson, Shabir A. Madhi, Cynthia G. Whitney, Keith P. Klugman
8. **The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect**  
Original Research Article

**Available online 16 May 2013**  
Samuele Calabro, Elaine Tritto, Annamaria Pezzotti, Marianna Taccone, Alessandro Muzzi, Sylvie Bertholet, Ennio De Gregorio, Derek T. O'Hagan, Barbara Baudner, Anja Seubert
9. **Immunogenicity and safety of pneumococcal conjugate polysaccharide and free polysaccharide vaccines alone or combined in HIV-infected adults in Brazil** Original Research Article

**Available online 16 May 2013**  
Yeh-Li Ho, Angela Pires Brandão, Maria Cristina de Cunto Brandileone, Marta Heloisa Lopes
10. **Post-vaccination serological test results of infants at risk of perinatal**

[\*\*transmission of hepatitis B using an intensified follow-up programme in a London centre\*\*](#) Original Research Article

**Available online 16 May 2013**

Cheuk Y.W. Tong, Carol Robson, Yin Wu, Rozanna Issa, Timothy Watts, Mark Wilkinson, Terry Wong, Ann Lorek

---

11. [\*\*Editorial\*\*](#)

**Available online 16 May 2013**

Bruce G. Weniger, Gregory M. Glenn

---

12. [\*\*Impact of pneumococcal conjugate vaccines on nasopharyngeal invasive disease among unvaccinated people: Review of evidence on indirect effects\*\*](#) Original Research Article

**Available online 16 May 2013**

Stephanie Davis, Maria Deloria-Knoll, Hilina T. Kassa, Katherine L. O'Brien

---

13. [\*\*Optimal targeting of seasonal influenza vaccination toward younger ages is robust to parameter uncertainty\*\*](#) Original Research Article

**Available online 16 May 2013**

Martial L. Ndeffo Mbah, Jan Medlock, Lauren Ancel Meyers, Alison P. Galvani, Jeffrey P. Townsend

---

14. [\*\*Functional evaluation of malaria Pfs25 DNA vaccine by \*in vivo\* electroporation in olive baboons\*\*](#) Original Research Article

**Available online 16 May 2013**

Rajesh Kumar, Ruth Nyakundi, Thomas Kariuki, Hastings Owzara, Onkoba Nyamongo, Godfree Mlambo, Barry Ellefsen, Drew Hannaman, Nirbhay Kumar

---

15. [\*\*Evaluation of virulent and live \*Shigella sonnei\* vaccine candidates in a gnotobiotic piglet model\*\*](#) Original Research Article

**Available online 15 May 2013**

Kwang-il Jeong, Malabi M. Venkatesan, Shoshana Barnoy, Saul Tzipori

---

16. [\*\*Trends in compliance with two-dose influenza vaccine recommendations among children aged 6 months through 8 years\*\*](#)

**Available online 15 May 2013**

Laura J. Pabst, Sandra S. Chaves, Cindy Weinbaum

---

17. [\*\*Hepatitis B virus vaccination in children with steroid sensitive nephrotic syndrome: Immunogenicity and safety?\*\*](#)

**Available online 15 May 2013**

N. Yıldız, L. Sever, Ö. Kasapçopur, F. Çullu, N. Arısoy, S. Çalışkan

18. [Prevalence of chronic hepatitis B virus infection after implementation of a hepatitis B vaccination program among children in three provinces in Cambodia](#) Original Research Article  
*Available online 15 May 2013*  
Mao Bunsoth, Minal K. Patel, Karen Hennessey, Richard J.W. Duncan, Kathleen Wannemuehler, Sann Chan Soeung
- 
19. [Effects of immunization of pregnant guinea pigs with guinea pig cytomegalovirus glycoprotein B on viral spread in the placenta](#) Original Research Article  
*Available online 15 May 2013*  
Kaede Hashimoto, Souichi Yamada, Harutaka Katano, Saki Fukuchi, Yuko Sato, Minami Kato, Toyofumi Yamaguchi, Kohji Moriishi, Naoki Inoue
- 
20. [Novel vaccine formulations against pertussis offer earlier onset of immunity and provide protection in the presence of maternal antibodies](#) Original Research Article  
*Available online 15 May 2013*  
Monika Polewicz, Aleksandra Gracia, Srinivas Garlapati, Jill van Kessel, Stacy Strom, Scott A. Halperin, Robert E.W. Hancock, Andrew A. Potter, Lorne A. Babiuk, Volker Gerdts
- 
21. [Developing Countries Vaccine Manufacturers Network \(DCVMN\): Engaging to step up for vaccine discovery and access. Meeting Report 2012](#)  
*Available online 15 May 2013*  
Sonia Pagliusi, Morena Makhoana, Mahima Datla, Luciana Leite, Jan Hendriks, Alireza Gholami, Weidan Huang, Yongzhong Gao, Suresh Jadhav, Gutla V.J.A. Harshavardhan, Yonglin Wu, Mahendra Suhardono, Akira Homma
- 
22. [Interferon-gamma production by mononuclear cells in Bacille Calmette-Guérin-revaccinated healthy volunteers predicted long-term antimycobacterial responses in a randomized controlled trial](#)  
*Available online 15 May 2013*  
Evelin S. Oliveira, Jamocyr M. Marinho, Theolis Barbosa, for the study group
- 
23. [SPI1 defective mutants of \*Salmonella enterica\* induce cross-protective immunity in chickens against challenge with serovars Typhimurium and Enteritidis](#) Original Research Article  
*Available online 15 May 2013*  
Marta Matulova, Hana Havlickova, Frantisek Sisak, Vladimir Babak, Ivan Rychlik
- 
24. [Multi-serotype outer membrane vesicles of \*Shigellae\* confer passive protection to the neonatal mice against shigellosis](#) Original Research Article  
*Available online 15 May 2013*

**Soma Mitra, Manoj K. Chakrabarti, Hemanta Koley**

25. [Influences on parental acceptance of HPV vaccination in demonstration projects in Uganda and Vietnam](#) Original Research Article

**Available online 15 May 2013**

**Sean R. Galagan, Proma Paul, Lysander Menezes, D. Scott LaMontagne**

26. [Changes in \*Streptococcus pneumoniae\* serotype distribution in invasive disease and nasopharyngeal carriage after the heptavalent pneumococcal conjugate vaccine introduction in Bogotá, Colombia](#) Original Research Article

**Available online 14 May 2013**

**Eliana L. Parra, Fernando De La Hoz, Paula L. Díaz, Olga Sanabria, María Elena Realpe, Jaime E. Moreno**

27. [High-dose vitamin A supplementation administered with vaccinations after 6 months of age: Sex-differential adverse reactions and morbidity](#) Original Research Article

**Available online 14 May 2013**

**Ane Bærent Fisker, Carlito Bale, Mathias Jul Jørgensen, Ibriama Balde, Linda Hornshøj, Bo Martin Bibby, Peter Aaby, Christine Stabell Benn**

28. [Distribution of carried pneumococcal clones in UK children following the introduction of the 7-valent pneumococcal conjugate vaccine: A 3-year cross-sectional population based analysis](#) Original Research Article

**Available online 13 May 2013**

**Anna S. Tocheva, Johanna M.C. Jefferies, M. Christodoulides, Saul N. Faust, Stuart C. Clarke**

## **Vaccine**

**Volume 31, Issue 21, Pages 2481-2538, 17 May 2013**

**Human Immune Response to Vaccines in the First Year of Life**

**Edited by Professor Willem Hanekom, Assist.Prof.Tobias R. Kollmann and Assist.Prof.Ofer Levy**

1. [Editorial Board/Aims and Scope](#)

**Pages C02**

2. [Vaccine-induced immunity in early life](#)

**Pages 2481-2482**

**Tobias R. Kollmann, Ofer Levy, Willem Hanekom**

**3. [Human immune responses to vaccines in the first year of life: Biological, socio-economic and ethical issues – A viewpoint](#) Review Article**

**Pages 2483-2488**

**M.O.C. Ota, O.T. Idoko, E.O. Ogundare, M.O. Afolabi**

**Highlights**

► Biological factors that affect the magnitude and quality of immune responses to vaccines. ► Socioeconomic factors that limit vaccine accessibility and evaluation. ► Strategies for circumventing these limitations in developing vaccines and evaluation of their immune responses.

**4. [Animal models for neonatal diseases in humans](#) Review Article**

**Pages 2489-2499**

**Benoît Levast, Sandra Schulz, Sylvia van Drunen Littel-van den Hurk, Volker Gerdts**

**Highlights**

► Review of animal models for infant vaccines. ► Respiratory infections. ► Enteric infections. ► Comparison of small and large animal models.

**5. [Immune response to vaccine adjuvants during the first year of life](#) Review Article**

**Pages 2500-2505**

**Ofer Levy, Stanislas Goriely, Tobias R. Kollmann**

**Highlights**

► We comprehensively reviewed mechanisms of action of licensed adjuvants. ► We examined the changes of adjuvant responses with age in early life. ► We juxtaposed the current knowledge with safety considerations. ► We point to the need for targeted investigations of adjuvant activity early in life.

**6. [Seroprotection after recombinant hepatitis B vaccination among newborn infants: A review](#) Review Article**

**Pages 2506-2516**

**Sarah F. Schillie, Trudy V. Murphy**

**Highlights**

► 98% of term infants attain seroprotection after hepatitis B vaccination. ► Seroprotection is reduced among infants with birth weights <2000g. ► Seroprotection does not vary with maternal HBsAg status, HBIG, or

schedule.

7. [\*\*Oral and inactivated poliovirus vaccines in the newborn: A review\*\*](#) Review Article

**Pages 2517-2524**

**Farrah J. Mateen, Russell T. Shinohara, Roland W. Sutter**

**Highlights**

- We reviewed the literature on the birth dose of poliovirus vaccines. ► Both oral and inactivated poliovirus vaccines were studied. ► Seroconversion was assessed in 26 studies from 13 countries (1959–2011).  
► There is great variability in the seroconversion following a birth dose of OPV. ► The utility of a dose of poliovirus vaccine at birth is confirmed.

8. [\*\*Immunization of newborns with bacterial conjugate vaccines\*\*](#) Review Article

**Pages 2525-2530**

**Anita H.J. van den Biggelaar, William S. Pomat**

**Highlights**

- We review bacterial conjugate vaccination trials in human newborns. ► Pneumococcal and *Haemophilus influenzae* type b conjugate vaccines are safe in newborns. ► Maternal immunization can be an alternative strategy to protect high-risk infants.

9. [\*\*The status of live viral vaccination in early life\*\*](#) Review Article

**Pages 2531-2537**

**Hayley A. Gans**

**Highlights**

- Review of current live viral vaccines used in infants. ► Review of obstacles to yearly life viral vaccination. ► Review of different routes of administration of viral vaccines.